Methods and systems for correlating the excretion of chemicals with corresponding genetic, medical and / or pathological conditions
By inducing massive cell death in target cell cultures and analyzing VOC emission data before and after treatment, a correlation was established between VOC profiles and genes and medical conditions. This solved the problem of the accuracy of the correlation between human chemical excretion and medical conditions, enabling personalized diagnosis and treatment selection.
Patent Information
- Application Number
- CN201980087788.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-11-03
- Filing Date
- 2019-11-04
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-11-04
AI Technical Summary
Existing technologies struggle to effectively link human respiration, the excretion of chemicals in bodily fluids, and genetic or medical conditions, resulting in insufficient accuracy in diagnosis and treatment selection.
By acquiring VOC emission data from target cell cultures, inducing massive cell death, and generating MCD in the target cell cultures, VOC emission data before and after treatment are analyzed to determine the treatment effect and efficacy. VOC data are acquired and processed using devices such as mass spectrometers to establish the correlation between VOC profiles and genes and medical conditions.
It enables precise diagnosis and treatment selection for individual patients, improves the accuracy of treatment effect assessment, can identify gene mutations and pathological conditions, and is applicable to the diagnosis and treatment monitoring of various medical conditions.
Smart Images

Figure CN113287012B_ABST
Abstract
Description
Technical Field
[0001] The disclosed technology generally relates to identifying chemical and / or cultural excretion in a human body, and specifically to methods and systems for correlating chemical and / or cultural excretion in a human body with corresponding genetic, medical and / or pathological conditions. Background Art
[0002] Metabolic, anabolism and / or catabolic processes produce chemical compounds. Some of the compounds belong to three groups of compounds, namely volatile organic compounds (VOC), semi-volatile organic compounds (SVOC) and volatile sulfur compounds (VSC). The compounds in these groups usually maintain a gaseous state at room temperature. Monitoring gases related to metabolic, anabolism and / or catabolic processes is known in the art. For example, monitoring oxygen (O2) saturation levels is used to monitor the patient's condition. Similarly, carbon dioxide (CO2) is used as an indicator for a wide range of lung-related diseases.
[0003] The publication "Summary of Safety and Probable Benefit, Menssana Research, Inc. Hearts Breath Test for Grade 3 Heart Transplant Rejection" relates to monitoring VOCs in the breath of heart transplant recipients to aid in the diagnosis of grade 3 heart transplant rejection.
[0004] The publication "A Review of the Volatiles From the Healthy Human Body" by de Lacy Costello et al. relates to a compendium of VOCs reported from healthy humans. In this compendium, a total of 1840 VOCs were identified in breath, saliva, urine, milk, blood, skin secretions, and feces. 872 were found in breath, 359 in saliva, 154 in blood, 256 in milk, 532 in skin secretions, 279 in urine, and 381 in feces.
[0005] The publication "The Application of Statistical Methods Using VOCs to Identify Patients with Lung Cancer" by Ulanowska et al. involves an attempt to determine a set of lung cancer biomarkers. For this purpose, breath samples were obtained from 137 patients diagnosed with lung cancer. The SPME-GC / MS method was used to analyze these samples. Exhaled breath was also obtained from 143 healthy volunteers with different smoking habits (active smokers, passive smokers and non-smokers). Statistical methods (such as discriminant analysis (DA) and CHAID model trees) were used for data processing and evaluation. Ulanowska proposed that chemotherapy treatment of lung cancer can be controlled by using molecular biomarkers, such as amino acids, peptides, lipids and carbohydrates, and it is defined as a molecule that reflects the pathological state of the organ and may be a characteristic pharmacological response to therapeutic intervention.
[0006] Altomare described in 2012 that breath analysis using a triple quadrupole gas chromatography-mass spectrometer (hereinafter referred to as "GC-MS / MS") can detect VOCs characteristic of specific conditions such as colorectal cancer and melanoma.
[0007] PCT Patent Application Publication WO 2014 / 180974 to Domingues Ortega, entitled "VOC-Based, Narcolepsy Diagnostic Method," relates to detecting narcolepsy in a patient by obtaining a sample from the subject and detecting the level of at least one VOC in the sample to obtain a VOC profile for the sample. Thereafter, the VOC profile of the sample is compared with a reference VOC profile to determine whether the patient suffers from narcolepsy. Summary of the invention
[0008] The goal of the disclosed technology is to provide a novel method and system for correlating the excretion of chemicals in at least one of a person's breath, body fluids, cell cultures with corresponding representations of genes or medical conditions, and using these correlations for diagnosis and / or determining treatment efficacy and / or determining treatment options.
[0009] According to an embodiment of the disclosed technology, a method for determining the effect of at least one selected treatment on a metabolic, anabolism, catabolism, genetic and / or medical condition administered to a patient is thus provided. The method includes the following procedures: obtaining VOC emission data of a target cell culture before treatment, and generating a pre-treatment target cell VOC profile from the VOC emission of the target cell culture before treatment. The method also includes a procedure for generating an MCD target cell VOC profile by:
[0010] (a) inducing massive cell death in untreated target cell cultures, thereby generating post-MCD target cell cultures; and
[0011] (b) Acquisition of VOC emission data of target cell culture after MCD.
[0012] The method also includes the following steps: applying at least one selected treatment to the target cell culture; for each selected treatment, obtaining VOC emission data of the target cell culture after treatment; and determining the effect of the selected treatment. The treatment is determined to be effective when the following occurs:
[0013] (a) the concentration value of the VOC emission data from the pre-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile is greater than the concentration value of the VOC emission data from the post-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile; and
[0014] (b) concentration values from the VOC emission data of the post-treatment target cell culture of VOCs associated with the MCD VOC profile emitted by the post-treatment target cell culture are greater than concentration values from the VOC emission data of the pre-treatment target cell culture of VOCs associated with the MCD VOC profile emitted by the pre-treatment target cell culture.
[0015] According to another aspect of the disclosed technology, there is thus provided a method for determining the efficacy of at least one selected treatment for a metabolic, anabolic, catabolic, genetic and / or medical condition administered to a patient. The method comprises the following procedures: obtaining pre-treatment patient VOC emission data of VOCs emitted from at least one of a breath sample and a body fluid sample before at least one selected phase of treatment; and obtaining pre-treatment VOC emission data of a target cell culture. The method also comprises procedures for generating a predicted MCD target cell VOC profile by:
[0016] (a) Inducing massive cell death in untreated target cell cultures, thereby generating post-MCD target cell cultures;
[0017] (b) obtaining VOC emission data of the target cell culture after MCD; and
[0018] (c) Use diffusion models to predict VOC concentration levels in breath and / or body fluids;
[0019] The method also includes the following procedures: applying the selected treatment to the patient; obtaining post-treatment patient VOC emission data of VOCs emitted from at least one of the breath samples and the body fluid samples obtained during and / or after at least one selected phase of the treatment; and determining the efficacy of the selected treatment. The treatment is determined to be effective when the concentration value of the VOCs in the MCD target cell VOC profile predicted during and / or after the selected phase of the treatment from the post-treatment patient VOC emission data associated with at least one of the breath samples and the body fluid samples is greater than the concentration value of the VOCs in the MCD target cell VOC profile predicted before the selected phase of the treatment from the pre-treatment patient VOC emission data associated with at least one of the breath samples and the body fluid samples.
[0020] According to another aspect of the disclosed technology, a method for determining the efficacy of a treatment administered to a patient is thus provided. The method includes the following procedures: obtaining at least one of a breath sample and a body fluid sample before at least one stage of the treatment; obtaining VOC emission data of VOCs emitted by at least one of the breath sample and the body fluid sample obtained before at least one stage of the treatment; and identifying a stored dynamic differential VOC profile corresponding to the obtained VOC emission data, thereby associating the pathological condition with the VOC emission data. The method also includes the following procedures: obtaining at least one of a breath sample and a body fluid sample during and / or after at least one stage of the treatment; obtaining VOC emission data of VOCs emitted in at least one of the breath sample and the body fluid sample obtained during and / or after at least one stage of the treatment; and classifying the efficacy of the treatment at least by comparing the concentration values of VOCs in the identified dynamic differential VOC profile obtained before at least one stage of the treatment with the concentration values of VOCs in the identified dynamic differential VOC profile obtained during and / or after at least one stage of the treatment. At least one phase of treatment is classified as successful when concentration levels of VOCs associated with the target cell VOC profile in the dynamic differential VOC profile decrease during and / or after a selected phase of treatment relative to concentration values of VOCs in the dynamic differential VOC profile identified prior to treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The disclosed technology will be more fully understood and appreciated from the following detailed description taken in conjunction with the accompanying drawings, in which:
[0022] Figure 1is a schematic diagram of a system constructed and operative in accordance with an embodiment of the disclosed technology for correlating between the excretion of chemicals in at least one of a person's breath, bodily fluids, cell cultures, and corresponding representations of genes or medical conditions, and employing these correlations for diagnosis and / or determination of treatment efficacy and / or determination of treatment selection;
[0023] Figure 2A and Figure 2B are schematic diagrams of VOC emission data and differential VOC profiles, respectively, according to another embodiment of the disclosed technology;
[0024] Figure 3A , Figure 3B and Figure 3C is a schematic diagram of an exemplary method for correlating VOC emissions with corresponding cancer types in a selected population, operated in accordance with another embodiment of the disclosed technology;
[0025] Figure 4A , Figure 4B , Figure 4C and Figure 4D is a schematic diagram of a method for correlating VOC emissions with target cells in a selected population before and after treatment, operated in accordance with another embodiment of the disclosed technology;
[0026] Figure 5A , Figure 5B and Figure 5C is a schematic diagram of a method for correlating a VOC profile with a pathological condition caused by a pathogen, operating in accordance with another embodiment of the disclosed technology;
[0027] FIG. 6A to FIG. 6D is a schematic diagram of a method for determining a dynamic differential VOC profile for a selected mismatch repair (MMR) gene activation therapy according to another embodiment of the disclosed technology;
[0028] Fig. 7A and Figure 7B is a schematic diagram of a method for determining a VOC profile of a target cell that has developed a therapy resistance mutation by a selected therapy, operated in accordance with another embodiment of the disclosed technology;
[0029] Fig. 8A and Figure 8B is a schematic diagram of an exemplary method for correlating VOC emissions with corresponding abnormal or pathological cells in an individual patient, operated in accordance with another embodiment of the disclosed technology;
[0030] Fig. 9A and Fig. 9Bis a schematic diagram of a method for correlating VOC emissions with corresponding target cells (e.g., oncogenic cells) in an individual patient before and after MCD, operating in accordance with another embodiment of the disclosed technology;
[0031] Fig. 10A , Fig. 10B and Fig. 10C is a schematic diagram of a method for identifying a personal treatment resistance VOC profile for an individual for a selected treatment, operating in accordance with another embodiment of the disclosed technology;
[0032] Fig.11 is a schematic diagram of a graph of exemplary three VOC emission data associated with breast cancer in a particular patient according to another embodiment of the disclosed technology;
[0033] Fig.12 is a schematic diagram of a method for determining efficacy of a treatment operated in accordance with another embodiment of the disclosed technology;
[0034] FIG. 13A to FIG. 13E is a schematic diagram of a method for determining efficacy of a treatment in an individual operated in accordance with another embodiment of the disclosed technology;
[0035] Fig.14 is a schematic diagram of a method for distinguishing between active mutations and inactive mutations in a patient and / or in culture operated according to another embodiment of the disclosed technology;
[0036] Fig.15A and Fig. 15B is a schematic diagram of a method for determining optimal treatment for a patient operated in accordance with another embodiment of the disclosed technology;
[0037] Fig.16 is a schematic diagram of an extended Farhi model operating in accordance with another embodiment of the disclosed technology; and
[0038] Fig.17A and Fig. 17B is a schematic diagram of a method for increasing VOC concentration prior to sampling and sampling a quantitative amount of air from a selected region of the lungs operated in accordance with another embodiment of the disclosed technology. DETAILED DESCRIPTION
[0039] The disclosed technology overcomes the shortcomings of the prior art by providing methods and systems for correlating the emission of chemicals (such as VOCs, SVOCs, and / or VSCs) in at least one of a person's breath, body fluids, or cell cultures with corresponding representations of genetic, medical, or pathological conditions. The correlation can then be employed to diagnose, determine therapeutic efficacy, or select a treatment for an individual patient or generally for a selected population. Genetic and / or medical and / or pathological conditions can include carcinogenic processes in their various stages, as well as conditions caused by pathogens (e.g., bacteria, viruses, fungi, etc.).
[0040] Typically, associating VOC emission data with corresponding genetic, medical, and / or pathological conditions includes: obtaining VOC emission data (e.g., using a mass spectrometer) for both healthy and unhealthy patients in vivo (e.g., exhaled breath), in vitro (e.g., cultured cells), or both; and determining a VOC profile associated with the genetic, medical, and / or pathological condition. The VOC profile can then be stored in a database and used at a later time for various purposes discussed further below. The terms 'VOC', 'VOC emission data', and 'VOC profile' will also be further explained below.
[0041] In addition, in this article, the term 'target cell' refers to any relevant cell in this article, which may exhibit genetic, medical and / or pathological conditions, cause genetic, medical and / or pathological conditions (e.g., cancer cells, cells infected with Alzheimer's disease, bacteria or viruses), or are related to genetic, medical and / or pathological conditions originating from inside or outside the body (e.g., papillomavirus may cause cervical cancer, so it is related to cervical cancer). Target cells can also be mutations of other target cells. For example, cancer cells are target cells. Moreover, bacteria, viruses and fungi can also be target cells. Infected tissue cells can also be target cells.
[0042] The term 'cell type' in this context relates to the type or arc from which the target cell originates. For example, breast cancer cells originate from cells that only occur in the breast. Another example is the drug-resistant strain Klebsiella pneumoniae carbapenemase (KPC), which originates from the drug-sensitive originating bacteria (arc type) - Klebsiella pneumoniae (KP).
[0043] The term 'culture' relates to at least one culture. The term 'culture' may also relate to a plurality of cultures, and may also refer to a plurality of cell cultures grown using different broth media and broth conditions. For example, KPC may be cultured in Mueller Hinton broth (MB) or Tryptic Soy Broth (TSB).
[0044] The term 'VOC' refers to any one or more chemical compounds found in an in vivo sample and / or in vitro sample (e.g., a breath sample, a urine sample, a blood sample, and / or a culture sample). For example, the term 'VOC' may refer to volatile organic compounds such as hydrocarbons, esters, aldehydes, and ketones, and may also refer to volatile sulfur-containing compounds such as dimethyl sulfide. The term 'VOC' may also refer to complex molecular metabolites and / or biological elements. For example, proteins, antibodies, enzymes, RNA, and DNA.
[0045] The term 'VOC emission data' relates at least to the presence or absence of one or more selected VOCs. VOC emission data may also refer to the concentration level of all VOCs or selected VOCs in a sample. VOC emission data may also relate to the mass spectrum, ion mobility and / or retention time (i.e., the time of elution from the GC chromatographic column) of one or more selected VOCs in the sample. VOC emission data may also relate to the full mass spectrum (molecular ions and fragments), ion mobility and / or retention time of all VOCs in the sample, either alone or in combination. For example, an analytical device (such as a gas chromatography field asymmetric ion mobility spectrometer mass spectrometer (GC-FAIMS-MS) etc.) may provide GC retention time separation information, mass spectrum and ion mobility information for each VOC detected. VOC emission data may be provided in units such as parts per million (ppm), parts per billion (ppb), parts per trillion (ppt). VOC emission data may also be provided in counting rate (e.g., parts per second, ppm per second, etc.). VOC emission data may be represented, for example, in vector or matrix form.
[0046] The term 'VOC profile' relates to VOC emission data associated with a corresponding metabolism, anabolism, catabolism, gene and / or medical condition (e.g., a healthy person, an unhealthy person, a carcinogenic process, a metabolic process, a cancer type, a bacterium, a virus or a fungus). A VOC profile may relate to a VOC concentration level, and may alternatively or additionally relate to a ratio between selected VOC concentration levels, or a pattern generated by some or all of the VOCs appearing in the VOC emission data, as further explained below. A VOC profile may serve as a template for VOC emission associated with a corresponding metabolism, anabolism, catabolism, gene and / or medical condition. In this article, the term 'healthy VOC profile' relates to a weighted average of VOC emission data associated with a healthy patient (i.e., from at least one of the following: breath, body fluids or cell cultures). Similarly, the term 'target cell VOC profile' relates to a weighted average of VOC emission data associated with a target (i.e., from at least one of the following: breath, body fluids or cell cultures). The term 'dynamic differential VOC profile' relates to the range of VOC emission data for each profile (i.e., healthy profile, target profile), and / or the range between a healthy VOC profile and a target VOC profile. In this document, the terms VOC emission data, healthy VOC profile, target VOC profile, and differential VOC profile may be followed by an adjective describing the related term, such as 'MCD pre-target cell VOC profile'.
[0047] Reference now Figure 1 , which is a schematic diagram of a system (generally designated 100) constructed and operated in accordance with an embodiment of the disclosed technology for correlating between the excretion of chemicals in at least one of a person's breath, body fluids, cell cultures and corresponding representations of genes or medical conditions, and employing these correlations for diagnosis and / or determining treatment efficacy and / or determining treatment selection. The system includes an analysis device 102, a database 104, and a processor 106. The system may also include a user interface 108. The processor 106 is coupled to the analysis device 102, the database 104, and the user interface 108.
[0048] The analysis device 102 can be a mass spectrometer (MS), an ion mobility spectrometer (IMS), a gas chromatograph (GC), various combinations of MS, GC, IMS, or any other device that provides identification and / or quantification of VOC analytes in a sample. The analysis device 102 is, for example, a triple quadrupole gas chromatograph mass spectrometer (GC-MS / MS), which may include a thermal dissolver and operate in a selected ion monitoring MS mode. Alternatively, the analysis device 102 can be a calibrated proton transfer reaction time-of-flight mass spectrometer (PTR-TOFMS) or a calibrated selected ion flow tube mass spectrometer (SIFT-MS), a field asymmetric ion mobility spectrometer (FAIMS), a gas chromatograph photon ionization detector or a field asymmetric ion mobility spectrometer time-of-flight mass spectrometer (FAIMS-TOFMS) or a gas chromatograph quadrupole time-of-flight (GC-QTOF) or a gas chromatograph Orbitrap (e.g., GC-exactive) or a gas chromatograph quadrupole mass spectrometer Orbitrap (GC-Q exactive) analysis device. The analysis device 102 is employed to obtain measurements of various chemicals, and in particular VOCs, in the breath or body fluids of a patient 110. The analysis device 102 is also employed to obtain measurements of various chemicals in a cell culture 112. The analysis device 102 provides the processor 106 with raw measurements.
[0049] The processor 106 correlates the discharge of the chemical with the corresponding metabolic process, anabolic process, catabolic process, genetic condition and / or medical condition and / or pathological condition, as further described below. The processor 106 also uses these correlations for diagnosis, for determining the efficacy of treatment and for selecting appropriate treatment, as also described in the following description.
[0050] Reference now Figure 2A and Figure 2B , which are schematic diagrams of VOC emission data (generally designated 120) and differential VOC profiles (generally designated 130), respectively, according to another embodiment of the disclosed technology. Figure 2A , the horizontal axis represents the selected VOC being measured, and the vertical axis represents the concentration level. As mentioned above, the concentration level can be measured in fractional notation (e.g., ppm, ppb, ppt) or as a count rate of VOC molecules. Typically, more than 1,800 different VOCs are secreted or found in typical human breath and body fluids. However, not all of these VOCs must be measured.
[0051] refer to Figure 2BThe dynamic differential VOC profile 130 is defined by a healthy VOC profile and a target VOC profile determined by VOC emission data of healthy cell cultures and target cell cultures, by VOC concentration levels predicted to be present in breath and / or body fluids and by measured VOC concentration levels in breath and / or body fluids. Figure 2B In the symbol 'X'132 T The symbol 'X' represents the VOC concentration level measured from healthy cell cultures 132 H Relative VOC concentration levels measured from target cell cultures. Line 134 T and line at 135 H The upper portion of the square 136 represents the target VOC concentration level predicted to be observed in the breath and / or body fluids and / or cell cultures of a patient having expression or overexpression of the target cell. H and online 135 T The portion of the lower square 136 represents the predicted healthy VOC concentration levels observed in the breath and / or body fluids and / or cell cultures of patients without expression or overexpression of the target cells. The predicted VOC concentration levels are determined by applying a diffusion model (e.g., the Farhi equation or the modified Farhi model, both of which are further explained below) and a cell growth equation to the VOC concentration levels measured from healthy cell cultures and target cell cultures. Square 136 represents the range of VOC emission data measured from the breath and / or body fluids of healthy patients and patients with expression or overexpression of the target cells. Line 135 T Represents the highest concentration level measured in the healthy patient group. Line 135 H Represents the lowest VOC concentration level measured in the patient group with expression or overexpression of the target cell. Online 135 T With 135 H The range between represents the threshold between the maximum normal VOC expression and the target cell VOC expression of the VOC in breath, body fluids or cell culture. H With 138 T The range between is the dynamic range of VOCs emitted in breath and / or body fluids. Figure 2A As shown, for example, when the measured concentration level is below a threshold, not all measured VOCs are included in the VOC profile 130 .
[0052] Building a VOC profile database
[0053] Reference now Figure 3A , Figure 3B and Figure 3C, which are schematic diagrams of an exemplary method for associating VOC emissions with corresponding cancer types in a selected population, operating in accordance with another embodiment of the disclosed technology. In procedure 150, at least one of a breath sample and a body fluid (e.g., blood, urine, or sweat) sample for each selected cancer type is obtained from a plurality of patients. The term 'cancer type' relates to the type of cancer (e.g., ovarian cancer, breast cancer, bladder cancer, skin cancer, colon cancer, etc.) and the genetic subtype of the cancer (e.g., HER2+, HER triple negative, etc.). Since the cancer type is known before the sample is obtained, each breath sample and body fluid sample is associated with the corresponding cancer type. After procedure 150, the method proceeds to procedure 160.
[0054] In process 152, target cell samples are obtained from a plurality of patients for each selected cancer type. FIG. 3A to FIG. 3C In the example shown in , the target cells are oncogenic cells of the corresponding cell type. For example, these target cell samples are obtained by a biopsy procedure. After procedure 152, the method proceeds to procedure 162.
[0055] In process 154, samples of healthy cells having the same cell type as the target cells are obtained from a plurality of patients. These healthy cell samples may also be obtained, for example, through a biopsy procedure. After process 154, the method proceeds to process 162.
[0056] In process 156, a sample of control cells of the same type as the target cells is obtained from the control subject. The control cells are healthy cells obtained from the control subject. The control cells can also be obtained, for example, by a biopsy procedure. After process 156, the method proceeds to process 162.
[0057] At step 158 , a breath sample and / or a body fluid sample is obtained from the control subject. After step 158 , the method proceeds to step 164 .
[0058] In process 160, VOC emission data of at least one of a breath sample and a body fluid sample of the patient is obtained. Figure 1 , the analysis device 102 acquires the emission data of at least one of breath and body fluids. After procedure 160 , the method proceeds to procedure 174 .
[0059] In procedure 162, the gene sequences of target cells, healthy cells, and control cells are determined. These gene sequences are then classified according to known oncogene mutations of the selected cancer type. For example, there are currently more than 315 known oncogene mutations. This procedure is also called molecular classification. After procedure 162, the method proceeds to procedure 166.
[0060] At process 164, VOC emission data is obtained for VOCs emitted from breath samples and / or body fluid samples of the control group. Figure 1 , the analysis device 102 obtains the emission data of at least one of the breath and the body fluid of the control group. After the process 164, the method proceeds to the process 176.
[0061] In process 166, the target cell sample, the healthy cell sample and the control cell sample are cultured. After process 166, the method proceeds to process 168.
[0062] In process 168, VOC emission data associated with the target cell culture, the healthy cell culture, and the control cell culture are obtained from the corresponding cultures. Figure 1 , the analysis device 102 acquires the emanation data related to the target cell culture, the healthy cell culture and the control cell culture from the corresponding cultures. After procedure 168 , the method proceeds to procedure 170 .
[0063] In procedure 170, for each gene sequence, a target cell VOC profile, a healthy cell VOC profile, and a control cell VOC profile are determined from the target cell culture VOC emission data, the healthy cell culture VOC emission data, and the control cell culture VOC emission data for each gene mutation. Initially, the target cell culture VOC emission data, the healthy cell culture VOC emission data, and the control cell culture VOC emission data are filtered. Typically, target cells and healthy cells may produce VOC artifacts that are not related to gene mutations. The target cell culture VOC emission data and the healthy cell culture VOC emission data are compared with each other and with the control cell VOC emission data to reduce the impact of irrelevant VOC artifacts, thereby better distinguishing VOCs related to selected gene mutations. For example, in some cases of breast cancer, healthy cells may still have oncogenes and / or may be in the process of becoming target cells. In some of such cases, the cancer may not yet be fully active. However, the expression of the gene should be a VOC, which will not be present in the control cell culture VOC emission data obtained from the control group and the breath sample and body fluid sample VOC emission data. Therefore, the expression of the gene in healthy cells can be identified. The filtered target cell culture VOC emission data is generated by comparing the target cell culture VOC emission data with the healthy cell culture VOC emission data and the control cell culture VOC emission data. Then, the filtered healthy cell culture VOC emission data is generated by comparing the healthy cell culture VOC emission data with the filtered target cell culture VOC emission data and the control cell culture VOC emission data. Afterwards, the filtered control cell culture VOC emission data is generated by comparing the control cell culture VOC emission data with the filtered healthy cell culture VOC emission data. Then, the target cell VOC profile is determined by comparing the filtered target cell culture VOC emission data with the filtered healthy cell culture VOC emission data and the filtered control cell culture VOC emission data. The healthy cell VOC profile is determined by comparing the filtered healthy cell culture VOC emission data to both the filtered target cell culture VOC emission data and the filtered control cell culture VOC emission data. The control cell VOC profile is determined by comparing the filtered control cell culture VOC emission data to the filtered healthy cell culture VOC emission data. Reference Figure 1 For each gene sequence, the processor 106 determines a target cell VOC profile, a healthy cell VOC profile, and a control cell VOC profile from the target cell culture VOC emission data, the healthy cell culture VOC emission data, and the control cell culture VOC emission data for each gene mutation. After procedure 170, the method proceeds to procedures 172 and 180.
[0064] In procedure 172, predicted target cell VOC profiles, predicted healthy cell VOC profiles, and predicted control cell VOC profiles are determined by predicting VOC concentration levels in breath and body fluids from the target cell VOC profiles, healthy cell VOC profiles, and control cell VOC profiles for each gene mutation. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Since the VOC profiles are associated with the corresponding gene mutations, the predicted VOC profiles are also associated with the corresponding gene mutations. Reference Figure 1 , the processor 106 determines a predicted target cell VOC profile, a predicted healthy cell VOC profile, and a predicted control cell VOC profile. After procedure 172 , the method proceeds to procedures 174 and 176 .
[0065] In procedure 174, a dynamic differential VOC profile is generated from the predicted target cell VOC profile, the predicted healthy cell VOC profile, and the VOC emission data of the patient's breath and body fluids. The dynamic differential VOC profile is generated by minimizing the error between the predicted target cell VOC profile, the predicted healthy cell VOC profile, and the VOC emission data of the breath sample and the body fluid sample. Since each predicted target cell VOC profile and predicted healthy cell VOC profile is associated with a corresponding gene mutation, each dynamic differential VOC profile is also associated with a corresponding gene mutation. Reference Figure 1 , the processor 106 determines a dynamic differential VOC profile for each gene mutation. From procedure 174 , the method proceeds to procedure 178 .
[0066] In process 176, a dynamic control VOC profile is generated from the predicted control cell VOC profile and the VOC emission data of the breath and body fluids of the control subject. Similar to the dynamic differential VOC profile, the dynamic control VOC profile is generated by minimizing the error between the predicted control cell VOC profile and the VOC emission data of the breath and body fluid samples of the control subject. Figure 1 , the processor 106 determines a dynamic control VOC profile for each gene mutation. From procedure 176 , the method proceeds to procedure 178 .
[0067] At process 178, the dynamic differential VOC profile is compared to the dynamic control VOC profile to further differentiate between them. Figure 1 , processor 106 compares the dynamic differential VOC profile to the dynamic control VOC profile to further differentiate therebetween. From procedure 178 , the method proceeds to procedure 180 .
[0068] In process 180, the VOC profile is stored in a database. Figure 1 , the processor 106 stores the dynamic differential VOC profile and the dynamic control VOC profile and the corresponding cancer types in the database 104 .
[0069] In some cases, VOC emissions from target cells and healthy cells may differ before and after treatment. For example, in oncogenic target cells, a massive cell death (MCD) treatment (e.g., radiation therapy, chemotherapy treatment) is used, and VOCs emitted by healthy cells and target cells may differ before and after MCD treatment. To determine the effect of MCD on VOCs emitted by a patient, MCD is induced in cell culture in a manner that does not generate VOC artifacts (e.g., by using rapid freezing techniques or ultraviolet-UV light techniques), and then the VOC emissions obtained before MCD and the VOC emissions obtained after MCD are associated with corresponding target cells of a selected population.
[0070] Now refer to 4A, Figure 4B , Figure 4C and Figure 4D , which are schematic diagrams of a method for correlating VOC emissions with target cells in a selected population before and after treatment, operating in accordance with another embodiment of the disclosed technology. In process 200, breath samples and / or body fluid samples are obtained from a plurality of patients for each selected target cell type. After process 200, the method proceeds to process 210.
[0071] In process 202, for each selected target cell type, target cell samples are obtained from a plurality of patients. For example, these target cell samples are obtained through a biopsy procedure. After process 202, the method proceeds to process 212.
[0072] In process 204, samples of healthy cells having the same cell type as the target cells are obtained from a plurality of patients. These healthy cell samples may also be obtained through a biopsy procedure. After process 204, the method proceeds to process 212.
[0073] In process 206, a sample of control cells of the same type as the target cells is obtained from the control group. These control cell samples may also be obtained through a biopsy procedure. After process 206, the method proceeds to process 212.
[0074] At step 208 , a breath sample and / or a body fluid sample is obtained from a control subject. After step 208 , the method proceeds to step 214 .
[0075] In process 210, VOC emission data of VOCs emitted in breath samples and / or body fluid samples are obtained from a plurality of patients. Figure 1, the analysis device 102 acquires the emission data of at least one of breath and body fluid from the plurality of patients. After procedure 210 , the method proceeds to procedure 236 .
[0076] In process 212 , the gene sequences of target cells, healthy cells and control cells are determined and classified according to molecular classification (gene classification). After process 212 , the method proceeds to process 216 .
[0077] At process 214, VOC emission data is obtained for VOCs emitted from breath samples and / or body fluid samples of the control group. Figure 1 , the analysis device 102 obtains the emission data of at least one of the breath and the body fluid of the control group. After the process 214, the method proceeds to the process 234.
[0078] In process 216, target cell culture, healthy cell culture and control cell culture are generated by culturing target cell, healthy cell and control cell samples. From process 216, the method proceeds to processes 218 and 220.
[0079] In process 218, VOC emission data associated with the target cell culture, the healthy cell culture, and the control cell culture are acquired prior to inducing MCD. Figure 1 Before inducing MCD, the analysis device 102 acquires VOC emission data of the target cells, healthy cells, and control cells. After procedure 218 , the method proceeds to procedures 220 and 222 .
[0080] In procedure 220, filtered pre-MCD target cell culture VOC emission data and filtered pre-MCD healthy cell culture VOC emission data, as well as filtered pre-MCD control cell culture VOC emission data, are generated for each gene sequence for each gene mutation to mitigate the effects of irrelevant VOC artifacts and to better distinguish VOCs associated with the selected gene mutation before inducing MCD. To this end, initially, filtered pre-MCD target cell culture VOC emission data are generated by comparing the target cell culture VOC emission data with both the healthy cell culture VOC emission data and the control cell culture VOC emission data, all of which are acquired before inducing MCD. Then, filtered pre-MCD healthy cell culture VOC emission data are generated by comparing the healthy cell culture VOC emission data (i.e., it is acquired before inducing MCD) with both the filtered pre-MCD target cell culture VOC emission data and the control cell culture VOC emission data acquired before inducing MCD (i.e., they are both acquired before inducing MCD). Thereafter, filtered control cell culture VOC emission data are determined by comparing control cell culture VOC emission data acquired prior to inducing MCD with filtered pre-MCD healthy cell culture VOC emission data. Figure 1 , the processor 106 determines the filtered pre-MCD target cell culture VOC emission data, the filtered pre-MCD healthy cell culture VOC emission data, and the filtered pre-MCD control cell culture VOC emission data for each gene sequence of each gene mutation. After procedure 220 , the method proceeds to procedures 228 , 230 , and 231 .
[0081] In procedure 222, massive cell death is induced in target cell cultures, healthy cell cultures, and control cell cultures. Preferably, MCD is induced in a manner that does not generate VOC artifacts (eg, by employing flash freezing techniques or UV light techniques).
[0082] In procedure 224, after the bulk cell death, VOC emission data associated with the target cell culture, the healthy cell culture, and the control cell culture are obtained from the respective cultures of the target cell culture, the healthy cell culture, and the control cell culture. It should be noted that the cell cultures used before and after MCD are the same cultures. Figure 1 After a large number of cells die, the analysis device 102 acquires VOC emission data of the target cells, healthy cells, and control cells. After procedure 222 , the method proceeds to procedure 226 .
[0083] In procedure 226, filtered post-MCD target cell culture VOC emission data and filtered post-MCD healthy cell culture VOC emission data, as well as filtered post-MCD control cell culture VOC emission data, are generated for each gene mutation to mitigate the effects of irrelevant VOC artifacts and to better distinguish VOCs associated with the selected gene mutation after inducing MCD. Initially, the filtered post-MCD target cell culture VOC emission data are generated by comparing the target cell culture VOC emission data acquired after inducing MCD with both the healthy cell culture VOC emission data acquired after inducing MCD and the control cell culture VOC emission data acquired after inducing MCD. Then, the filtered post-MCD healthy cell culture VOC emission data are generated by comparing the healthy cell culture VOC emission data (i.e., acquired after inducing MCD) with both the filtered post-MCD target cell culture VOC emission data and the control cell culture VOC emission data (i.e., acquired after inducing MCD). A filtered control cell culture VOC profile is then determined by comparing the control cell culture VOC emission data (ie, acquired after induction of MCD) to the filtered post-MCD healthy cell culture VOC emissions. Figure 1 , the processor 106 determines the filtered post-MCD target cell culture VOC emission data, the filtered post-MCD healthy cell culture VOC emission data, and the filtered post-MCD control cell culture VOC emission data for each gene sequence for each gene mutation. After procedure 226 , the method proceeds to procedures 228 , 230 , and 231 .
[0084] In procedure 228, a pre-MCD target cell VOC profile and a post-MCD target cell VOC profile are determined from the filtered pre-MCD target cell VOC emission data and the filtered post-MCD target cell VOC emission data. Figure 1 The processor 106 determines the MCD pre-target cell VOC profile and the MCD post-target cell VOC profile from the filtered MCS pre-target cell VOC emission data and the filtered MCD post-target cell VOC emission data. After procedure 228 , the method proceeds to procedure 232 .
[0085] In process 230, a pre-MCD healthy cell VOC profile and a post-MCD healthy cell VOC profile are determined from the filtered pre-MCD healthy cell culture VOC emission data and the filtered post-MCD healthy cell culture VOC emission data. Figure 1The processor 106 determines a pre-MCD healthy cell VOC profile and a post-MCD healthy cell VOC profile from the filtered pre-MCD healthy cell culture VOC emission data and the filtered post-MCD healthy cell culture VOC emission data. After procedure 230 , the method proceeds to procedure 232 .
[0086] In procedure 231, a pre-MCD control cell VOC profile and a post-MCD control cell VOC profile are determined from the filtered pre-MCD control cell culture VOC emission data and the filtered post-MCD control cell culture VOC emission data. Figure 1 The processor 106 determines a pre-MCD control cell VOC profile and a post-MCD control cell VOC profile from the filtered pre-MCD control cell culture VOC emission data and the filtered post-MCD control cell culture VOC emission data. After procedure 231 , the method proceeds to procedure 232 .
[0087] In procedure 232, for each gene mutation, a predicted target cell VOC profile, a predicted healthy VOC profile, and a predicted control cell VOC profile are determined. The predicted target cell VOC profile is determined by predicting the VOC concentration levels in breath and body fluids from the target cell VOC profile before MCD and the target cell VOC profile after MCD. The predicted healthy cell VOC profile is determined by predicting the VOC concentration levels in breath and body fluids from the healthy cell VOC profile before MCD and the healthy cell VOC profile after MCD. The predicted control cell VOC profile is determined by predicting the VOC concentration levels in breath and body fluids from the control cell VOC profile before MCD and the control cell VOC profile after MCD. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Reference Figure 1 , the processor 106 determines a predicted target cell VOC profile, a predicted healthy cell VOC profile, and a predicted control cell VOC profile. After procedure 232 , the method proceeds to procedures 234 , 236 , and 240 .
[0088] In process 234, a dynamic control cell VOC profile is generated from the predicted control cell VOC profile and the VOC emission data of the breath and body fluids of the control subject. Similar to the dynamic differential VOC profile, the dynamic control VOC profile is generated by minimizing the error between the predicted control cell VOC profile and the VOC emission data of the breath and body fluid samples of the control subject. Figure 1 , the processor 106 determines a dynamic control VOC profile for each gene mutation. After procedure 234 , the method proceeds to procedure 238 .
[0089] In procedure 236, for each genetic mutation, a dynamic differential VOC profile is generated from the predicted target cell VOC profile, the predicted healthy cell VOC profile, and the breath and / or body fluid VOC emission data. Figure 1 The processor 106 generates a dynamic differential VOC profile for each gene mutation from the predicted target cell VOC profile, the predicted healthy cell VOC profile, and the breath sample and / or body fluid sample VOC emission data. After procedure 236 , the method proceeds to procedure 238 .
[0090] At process 238, the dynamic differential VOC profile is compared to the dynamic control VOC profile to further differentiate between them. Figure 1 , the processor 106 compares the dynamic differential VOC profile to the dynamic control VOC profile to further differentiate therebetween. After procedure 238 , the method proceeds to procedure 240 .
[0091] In process 240, the dynamic differential VOC profile and the dynamic control VOC profile are stored in a database. Figure 1 , the processor 106 stores the dynamic differential VOC profile and the dynamic control VOC profile in the database 104 .
[0092] According to another aspect of the disclosed technology, VOC emissions from the body and / or culture of one or more patients can be associated with known pathological conditions caused by pathogens such as bacteria, viruses, fungi, etc. (e.g., normal flora or pathological flora). In some cases (e.g., E. coli), these pathogens may exist naturally in the body, and the pathological condition is characterized by an increase or decrease in the number of such pathogens. Pathological conditions may also exhibit different VOC emissions before and after treatment due to VOC artifacts related to the effect of the treatment on other bacteria or pathogens in the body (e.g., VOC artifacts related to the effect of antibiotics on normal flora in the intestine).
[0093] Reference now Figure 5A , Figure 5B and Figure 5C , which are schematic illustrations of a method for correlating VOC profiles with pathological conditions caused by pathogens, operating in accordance with another embodiment of the disclosed technology.
[0094] At procedure 250, at least one of the breath samples and / or body fluid samples is obtained from a plurality of patients having abnormal target cell levels before the patients receive any treatment related to the target cells (e.g., in the case of a bacterial pathogen such as Klebsiella pneumoniae, before the patients take antibiotics), and at least one of the breath samples and / or body fluid samples is obtained from the same plurality of patients after the patients have completed treatment (i.e., the pathogen is no longer symptomatic and / or is no longer present in the patient's culture). It should be noted that the samples collected after successful treatment are collected after a period of time that includes a period of time necessary for the effects of the treatment to completely wear off, so that VOC artifacts directly or indirectly related to the treatment are no longer present in the samples. After procedure 250, the method proceeds to procedure 258.
[0095] At step 252, at least one of a breath sample and a body fluid sample is obtained from a plurality of patients having normal target cell levels. After step 252, the method proceeds to step 258.
[0096] At step 254, prior to any treatment, target cell samples are obtained from a plurality of patients having abnormal target cell levels. After step 254, the method proceeds to step 260.
[0097] At step 256, target cell samples are obtained from a plurality of patients having normal target cell levels. After step 256, the method proceeds to step 260.
[0098] At process 258, VOC emission data of VOCs emitted in at least one of breath samples and / or body fluid samples are obtained from patients with abnormal target cell levels before and after treatment (i.e., when treatment is successful). Additionally, VOC emission data of VOCs emitted in at least one of breath samples and / or body fluid samples are obtained from patients with normal target cell levels. Figure 1 , the analysis device 102 obtains emission data of VOCs emitted from at least one of a breath sample and a body fluid sample obtained from a patient with abnormal target cell levels before any treatment, and emission data of VOCs emitted from at least one of a breath sample and a body fluid sample obtained after a successful treatment involving target cells (the samples are obtained from the same multiple patients before and after the treatment). The analysis device 102 also obtains VOC emission data of VOCs emitted from at least one of a breath sample and / or a body fluid sample from multiple patients with normal target cell levels. It should be noted that the group of multiple patients with abnormal target cell levels and the group of multiple patients with normal target cell levels are two different groups. After procedure 258, the method proceeds to procedures 259 and 282.
[0099] In procedure 259, a respiratory and / or body fluid target VOC profile and a respiratory and / or body fluid healthy VOC profile are determined. The respiratory and / or body fluid target VOC profile is determined by comparing VOC emission data acquired from multiple patients with abnormal target cell levels before treatment with VOC emission data acquired from the same multiple patients with abnormal target cell levels after successful treatment and VOC emission data acquired from patients with normal target cell levels. The respiratory and / or body fluid healthy VOC profile is determined by comparing the respiratory and / or body fluid VOC emission data from multiple patients with normal target cell levels with the respiratory and / or body fluid target VOC profile. Reference Figure 1 , processor 106 determines a breath and / or body fluid target VOC profile and a breath and / or body fluid healthy VOC profile. After procedure 259 , the method proceeds to procedures 274 and 276 .
[0100] In procedure 260, the gene sequences of target cells from both patients with abnormal target cell levels and patients with normal target cell levels are determined, and the target cells are classified. For molecular classification, the gene sequences of target cells from patients with abnormal target cell levels and patients with normal target cell levels are determined, and the target cells from patients with abnormal target cell levels are tested for mutations. After procedure 260, the method proceeds to procedure 262.
[0101] In step 262, target cell cultures and normal cell cultures are produced by culturing cells from a cell sample from a patient with abnormal target cell levels and cells from a cell sample from a patient with normal target cell levels, respectively. After step 262, the method proceeds to steps 264 and 266.
[0102] In process 264, VOC emission data is obtained regarding VOCs emitted by cells in the target cell culture and the normal cell culture prior to inducing MCD. Figure 1 Before inducing MCD, the analysis device 102 acquires VOC emission data related to VOCs emitted by the target cell culture and the normal cell culture. After procedure 264, the method proceeds to procedures 266 and 270.
[0103] In procedure 266, massive cell death is induced on cells in the target cell culture and the normal cell culture. Similar to the above, MCD is induced in a manner that does not produce VOC artifacts (e.g., flash freezing, UV light). After procedure 266, the method proceeds to procedure 268.
[0104] In procedure 268, after inducing MCD, VOC emission data is acquired regarding VOCs emitted by cells in the target cell culture and the normal cell culture. It should be noted that the cell culture used to acquire VOC emission data after MCD is the same as the cell culture used to acquire VOCs before MCD. Figure 1 After inducing MCD, the analysis device 102 acquires VOC emission data related to VOCs emitted by the cell culture. After process 268, the method proceeds to process 272.
[0105] In procedure 270, target cell culture VOC emission data acquired prior to inducing MCD is compared to normal cell culture VOC emission data acquired prior to inducing MCD to differentiate between them. The target cell culture VOC emission data relates to VOC emission data of cell cultures derived from patients with abnormal target cell levels prior to any treatment. The normal VOC emission data relates to VOC emission data of cell cultures derived from patients with normal target cell levels. Figure 1 , the processor 106 compares the target cell culture VOC emission data before inducing MCD with the normal cell culture VOC emission data to distinguish between them. After procedure 270 , the method proceeds to procedure 274 .
[0106] In process 272, the target cell culture VOC emission data acquired after inducing MCD is compared with the normal cell culture VOC emission data acquired after inducing MCD to distinguish therebetween. Figure 1 , the processor 106 compares the target cell culture VOC emission data acquired after inducing MCD with the normal cell culture VOC emission data acquired after inducing MCD to distinguish therebetween. After procedure 272 , the method proceeds to procedure 276 .
[0107] In process 274, a pre-MCD target cell VOC profile and a post-MCD target cell VOC profile are generated. These profiles are generated by comparing target cell culture VOC emission data acquired before inducing MCD with both target cell culture VOC emission data and respiratory and / or body fluid target VOC profiles acquired after inducing MCD. Figure 1 Processor 106 generates a pre-MCD target cell VOC profile and a post-MCD target cell VOC profile by comparing the target cell culture VOC emission data acquired before inducing MCD with both the target cell culture VOC emission data acquired after inducing MCD and the respiratory and / or bodily fluid target VOC profile. After procedure 274, the method proceeds to procedure 278.
[0108] In process 276, a pre-MCD normal cell VOC profile and a post-MCD normal cell VOC profile are generated. These profiles are generated by comparing normal cell culture VOC emission data acquired before inducing MCD with both normal cell culture VOC emission data acquired after inducing MCD and respiratory and / or body fluid health VOC profiles. Figure 1 Processor 106 generates a pre-MCD normal cell VOC profile and a post-MCD normal cell VOC profile by comparing normal cell culture VOC emission data acquired before inducing MCD with normal cell culture VOC emission data acquired after inducing MCD and the respiratory and / or body fluid health VOC profile. After procedure 276, the method proceeds to procedure 278.
[0109] In procedure 278, a predicted target VOC profile and a predicted target VOC profile are determined. The predicted target VOC profile is determined by predicting the concentration levels in breath and body fluids from the pre-MCD target cell VOC profile and the post-MCD target cell VOC profile. The predicted healthy VOC profile is determined by predicting the concentration levels in breath and body fluids from the pre-MCD healthy cell VOC profile and the post-MCD healthy cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Reference Figure 1 , the processor 106 determines a predicted target VOC profile and a predicted healthy VOC profile. After procedure 278 , the method proceeds to procedures 280 and 282 .
[0110] In process 280, an abnormal response VOC profile and a normal response VOC profile related to the patient's response to the target cell are generated by comparing the breath and / or body fluid VOC emission data from multiple patients with abnormal target cell levels with the breath and / or body fluid VOC emission data from multiple patients with normal target cell levels, the predicted target VOC profile, and the predicted healthy VOC profile. These normal response VOC profiles and abnormal response VOC profiles are related to the patient's response to the target cell (e.g., immune system, antibody production). Reference Figure 1 , the processor 106 generates an abnormal response VOC profile and a normal response VOC profile related to the patient's response to the target cell by comparing the breath and / or body fluid VOC emission data from a plurality of patients with abnormal target cell levels with the breath and / or body fluid VOC emission data from a plurality of patients with normal target cell levels, the predicted target VOC profile, and the predicted healthy VOC profile. After procedure 280, the method proceeds to procedures 282 and 284.
[0111] In process 282, a dynamic differential VOC profile is generated from the predicted target VOC profile, the predicted healthy VOC profile, the abnormal response VOC profile, the normal response VOC profile, the breath and / or body fluid VOC emission data from multiple patients with abnormal target cell levels, and the breath and / or body fluid VOC emission data from multiple patients with normal target cell levels. Figure 1 , the processor 106 generates a dynamic differential VOC profile. After procedure 282, the method proceeds to procedure 284.
[0112] In process 284, the VOC profile is stored in a database. Figure 1 , the processor 106 stores the VOC profile in the database 104 .
[0113] According to another embodiment of the disclosed technology, VOC emissions from one or more patient bodies can be correlated with exposure of target cells to MMR activating treatments by determining a dynamic differential VOC profile for each selected mismatch repair (MMR) gene activation therapy. FIG. 6A to FIG. 6D , which are schematic diagrams of a method for determining a dynamic differential VOC profile for a selected mismatch repair (MMR) gene activation therapy according to another embodiment of the disclosed technology.
[0114] In process 300, for each selected gene, before applying MMR gene activation therapy, a breath sample and / or a body fluid sample is obtained from a plurality of patients. The gene is selected from genes suitable for MMR gene activation therapy. After process 300, the method proceeds to process 302.
[0115] In process 302, VOC emission data of VOCs emitted in a breath sample and / or a body fluid sample is obtained. Figure 1 , the analysis device 102 acquires VOC emission data of the breath sample and / or the body fluid sample. From procedure 302 , the method proceeds to procedure 348 .
[0116] In process 304, for each selected gene, target cell samples are obtained from a plurality of patients. From process 304, the method proceeds to process 308.
[0117] In process 306 , for each selected gene, a sample of healthy cells of the same type as the target cells is obtained from the same plurality of patients (ie, for each selected gene, a set of target cells and healthy cells is obtained from each patient in the plurality of patients). From process 306 , the method proceeds to process 308 .
[0118] In process 308, two target cell culture groups and a healthy cell culture are generated from the target cell sample and the healthy cell sample. For clarity of the following explanation, the first of the target cell culture groups is referred to as 'culture group A', and the second of the target cell culture groups is referred to as 'culture group B'. From process 308, the method proceeds to process 310.
[0119] In process 310, pre-treatment VOC emission data is obtained for cells in two target cell culture groups (ie, culture group A and culture group B) and healthy cell cultures. Figure 1 The analysis device 102 acquires VOC emission data related to the two target cell cultures and the healthy cell culture. The method proceeds from procedure 310 to procedures 312, 328, 330, and 331.
[0120] In procedure 312, the gene sequences of the target cells in the two target cell culture groups (i.e., culture group A and culture group B) and the healthy cells in the healthy cell culture are verified. When determining the dynamic differential VOC profile for MMR gene activation therapy, the gene sequence of the target cells is known and should only be verified, and the healthy cell culture is genetically sequenced to ensure the absence of a pathological process or condition, or to determine the level of a pathological process or condition. From procedure 312, the method proceeds to procedure 314.
[0121] In procedure 314, a pre-treatment target cell VOC profile for each of the target cells and a pre-treatment healthy cell VOC profile for each of the healthy cells are determined by comparing the target cell culture VOC emission data for the two target cell culture groups (i.e., culture group A and culture group B) with the healthy cell culture VOC emission data for the healthy cell culture. Figure 1 , the processor 106 determines the pre-treatment target VOC profile and the pre-treatment healthy VOC profile. From procedure 314 , the method proceeds to procedures 316 , 318 , 320 , 340 .
[0122] At process 316 , the selected MMR gene activation therapy is applied to cells in the first of the two target cell culture groups (ie, culture group A). From process 316 , the method proceeds to process 322 .
[0123] At procedure 318, a large amount of cell death is induced on cells in the second of the two target cell culture groups that have not been exposed to any treatment (i.e., culture group B) in a manner that does not generate residual VOC artifacts (e.g., by using a flash freezing technique or ultraviolet-UV light technique on the target cell culture). From procedure 318, the method proceeds to procedure 324.
[0124] In process 320, MMR gene activation therapy is applied to cells in healthy cell culture. From process 320, the method proceeds to process 326.
[0125] In process 322, after applying the selected MMR gene activation therapy, post-treatment target cell culture VOC emission data associated with target cells in a first group of target cell cultures (ie, culture group A) is obtained. Figure 1 After applying the MMR gene activation therapy, the analysis device 102 acquires post-treatment target cell culture VOC emission data associated with the target cells in the culture group A. After procedure 322 , the method proceeds to procedure 328 .
[0126] In procedure 324, after inducing MCD, post-MCD target cell culture VOC emission data is acquired associated with target cells in a second set of target cell cultures (ie, culture set B). Figure 1 After inducing MCD, the analysis device 102 acquires post-MCD target cell culture VOC emission data associated with the target cells in culture group B. After procedure 324 , the method proceeds to procedure 330 .
[0127] In process 326, after the selected MMR gene activation treatment, post-treatment healthy cell culture VOC emission data associated with the healthy cell culture is obtained. Figure 1 After applying the MMR gene activation therapy, the analysis device 102 obtains post-treatment healthy cell culture VOC emission data related to the healthy cell culture. After process 326, the method proceeds to process 332.
[0128] In procedure 328, an MMR gene activation target VOC profile is generated by comparing pre-treatment target cell culture VOC emission data of target cells obtained from target cells in a first set of target cell cultures (i.e., culture set A) with post-treatment target cell culture VOC emission data of target cells obtained from target cells in a first set of target cell cultures (i.e., culture set A). The MMR gene activation target VOC profile relates to VOCs emitted by the target cell culture when a selected MMR gene activation treatment is applied. Figure 1 , the processor 106 generates an MMR gene activation target VOC profile by comparing pre-treatment target cell culture VOC emission data of target cells obtained from target cells in the first set of target cell cultures with post-treatment target cell culture VOC emission data of target cells obtained from target cells in the first set of target cell cultures after being subjected to the selected MMR gene activation therapy. After procedure 328, the method proceeds to procedure 334.
[0129] In procedure 330, a post-MCD VOC profile is generated by comparing pre-treatment target cell culture VOC emission data of target cells obtained from target cells in a second set of target cell cultures (i.e., culture set B) with post-MCD target cell culture VOC emission data of target cells obtained from target cells in a second set of target cell cultures (i.e., culture set B) after inducing MCD. The post-MCD target cell VOC profile relates to VOCs emitted by target cell culture 'B' when MCD is induced in a manner that does not generate residual VOCs. Reference Figure 1 The processor 106 generates a post-MCD target cell VOC profile by comparing the pre-treatment target cell culture VOC emission data of the target cells obtained from the target cells in the second set of target cell cultures before MCD with the post-MCD target cell culture VOC emission data of the target cells obtained from the target cells in the second set of target cell cultures after inducing MCD. After procedure 330, the method proceeds to procedure 336.
[0130] In process 332, an MMR gene activated healthy cell VOC profile is generated by comparing the pre-treatment healthy cell culture VOC emission data of the healthy cells with the post-treatment VOC emission data of the healthy cells. The MMR gene activated healthy cell VOC profile relates to VOCs emitted by the healthy cell culture when the selected MMR gene activation treatment is applied. Figure 1 The processor 106 generates the MMR gene activated healthy cell VOC profile by comparing the pre-treatment healthy cell culture VOC emission data of the healthy cells with the post-treatment healthy cell culture VOC emission data of the healthy cells. After procedure 332 , the method proceeds to procedure 338 .
[0131] In procedure 334, a predicted MMR gene activated target cell VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the MMR gene activated target cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1 , the processor 106 determines the predicted MMR gene activation target cell VOC profile. After procedure 334, the method proceeds to procedure 342.
[0132] In procedure 336, a predicted post-MCD target cell VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the post-MCD target cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1, the processor 106 determines a predicted post-MCD target cell VOC profile. After procedure 336 , the method proceeds to procedure 342 .
[0133] In procedure 338, a predicted MMR gene activated healthy cell VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the MMR gene activated healthy cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Reference Figure 1 , the processor 106 determines a predicted MMR gene activated healthy cell VOC profile. After procedure 338, the method proceeds to procedure 342.
[0134] In process 342, the patient MMR gene activation therapy is started. After process 342, the method proceeds to process 344.
[0135] At step 344, at least one of a breath sample and a body fluid sample is obtained from the plurality of patients during and / or after at least one selected phase of the selected MMR gene activation therapy. After step 344, the method proceeds to step 346.
[0136] At process 346, VOC emission data of VOCs emitted from a breath sample and / or a body fluid sample of the patient is obtained at at least one selected stage of the selected MMR gene activation therapy. Figure 1 After step 346 , the method proceeds to step 348 .
[0137] In procedure 348, a dynamic differential VOC profile for each selected gene mutation is generated from the predicted MMR gene activated target cell VOC profile, the predicted MCD target cell VOC profile, the predicted MMR gene activated healthy cell VOC profile, and the breath and / or body fluid VOC emission data of multiple patients before and after treatment. It should be noted that for each patient, the breath and / or body fluid VOC emission data from samples collected before MMR gene activation treatment and the breath and / or body fluid VOC emission data from samples collected during or after treatment must be collected from the same patient. Reference Figure 1 Processor 106 generates a dynamic differential VOC profile from the predicted MMR gene activated target cell VOC profile, the predicted MCD target cell VOC profile, the predicted MMR gene activated healthy cell VOC profile, and the VOC emission data of the plurality of patients before and during or after treatment with the MMR gene activation therapy. After procedure 348, the method proceeds to procedure 350.
[0138] In process 350, the VOC profile is stored in a database. Figure 1 , the processor 106 stores the VOC profile in the database 104 .
[0139] Measuring VOCs can also be used to determine whether a target cell has formed one or more treatment resistance mutations. In addition, when subjected to the same treatment or different treatments, mutated target cells may cause other mutations. Different treatments can be the same type of treatment (e.g., chemotherapy, radiotherapy, or antibiotics) with different doses of therapeutic agents, or different types of treatments. In other words, treatments may cause mutation generations. For example, TP-53 type target cells of lung cancer may mutate into KSR type target cells when subjected to one treatment. KSR type target cells may mutate into another type of lung cancer target cells when subjected to the same or another treatment. For this purpose, before and after being subjected to a treatment known to trigger the formation of one or more treatment resistance mutations, VOC emission data of a target cell culture known to form one or more treatment resistance mutations is obtained. The culture before and after the treatment is the same culture. The VOC emission data of a target cell culture that forms one or more treatment resistance mutations (verified by gene sequencing) is compared with the VOC emission data of the culture before the application of the treatment. This process may be repeated several times for the same treatment, and / or for different treatments, the process may be repeated several times. A complex therapy resistant target cell VOC profile is generated, which includes target cell VOC profiles of all or a selected one of the mutational generations. The term 'type' of target cell herein relates to a target cell that may or may not have mutated from other target cells, or to a target cell that has or has not been previously treated. Reference is now made to Fig. 7A and Figure 7B , which are schematic diagrams of a method for determining a VOC profile of a target cell that has developed a therapy-resistance mutation through a selected therapy, operated in accordance with another embodiment of the disclosed technology.
[0140] In process 400, cell cultures of respective selected types of target cells known to develop therapeutic resistance mutations are generated. After process 400, the method proceeds to process 402.
[0141] In process 402, prior to administering a treatment, VOC emission data related to VOCs emitted by target cells in a target cell culture is obtained. Figure 1 , the analysis device 102 acquires VOC emission data from the target cell culture related to VOCs emitted by the target cells prior to treatment. After procedure 402 , the method proceeds to procedure 404 and procedure 414 .
[0142] In step 404, a treatment known to produce one or more treatment resistance mutations is applied to the target cell culture. After step 404, the method proceeds to step 406.
[0143] At step 406 , target cells that have developed resistance to treatment are identified in the treated target cell culture, for example, by using microscopic scanning. After step 406 , the method proceeds to step 408 .
[0144] At step 408, for each identified target cell with a therapy resistance mutation (i.e., after application of the selected therapy), a corresponding mutant target cell culture is generated. In other words, new cultures of these target cells with therapy resistance mutations are created separately so that the selected therapy can be applied to the new cultures in order to identify additional therapy resistance mutations. After step 408, the method proceeds to step 410.
[0145] In step 410, target cells identified as developing treatment resistance mutations are subjected to genetic sequencing to determine the one or more mutations (ie, if present) and to identify the molecular classification of the target cells after treatment. After step 410, the method proceeds to step 412.
[0146] In process 412, VOC emission data associated with the mutant target cells is obtained from the corresponding mutant target cell culture. Figure 1 , the analysis device 102 acquires VOC emission data from the mutant target cell culture. After process 412 , the method proceeds to process 414 .
[0147] At process 414, a treatment resistant target cell VOC profile is generated by comparing the pre-treatment target cell culture VOC emission data (ie, the VOC emission data of the target cell culture before treatment) with the mutant target cell culture VOC emission data of the mutant cell culture. Figure 1 The processor 106 generates a treatment resistance VOC profile by comparing the VOC emission data of the target cell culture before any treatment with the target cell culture VOC emission data of the mutant target cell culture. After procedure 414, the method proceeds to procedure 416.
[0148] At process 416, a complex therapy resistance VOC profile is determined. The complex therapy resistance VOC profile includes information about the VOC profiles of therapy resistant target cells from a selected number of mutation generations. Figure 1 , the processor 106 determines a complex therapy resistance VOC profile. After procedure 416 , the method proceeds to procedure 418 .
[0149] In process 418, a predicted complex therapy resistance VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the complex therapy resistance VOC profile. The VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1 , the processor 106 determines a predicted complex therapy resistance VOC profile. After procedure 418 , the method proceeds to procedure 420 .
[0150] At process 420, the predicted treatment-resistant VOC profile is stored in a database. Figure 1 , the processor 106 stores the predicted treatment-resistant VOC profile in the database 104 .
[0151] It should be noted that for a selected number of treatments or mutations or both, Fig. 7A and Figure 7B The complex therapy resistance VOC profile incorporates information from each of these replicates. The above stored therapy resistance VOC profiles can be used to identify an individual's personal therapy resistance VOC profile.
[0152] Determining an individual's VOC profile
[0153] Similar to determining the VOC profile of the general population, the VOC profile of an individual can be determined. As mentioned above, according to the disclosed technology, VOC emissions from the body of one or more patients can be associated with corresponding cancer types caused by one or more cell gene mutations, for example. The following is an example of associating VOC emissions from the body of an individual patient with corresponding cancer types caused by cell gene mutations. However, the technology can also be applied to any form and type of cells.
[0154] Reference now Fig. 8A and Figure 8B , which are schematic diagrams of an exemplary method for correlating VOC emissions with corresponding abnormal or pathological cells in an individual patient, operating in accordance with another embodiment of the disclosed technology. Fig. 8A and Figure 8B In, exemplary pathological cells are forms of cancer types.
[0155] In procedure 450, at least one of a breath sample and a body fluid (e.g., blood, urine, or sweat) sample is obtained from a patient for a selected cell gene mutation. Cell gene mutations may be associated with cancer types. The term 'cancer type' relates to the type of cancer (e.g., ovarian cancer, breast cancer, bladder cancer, skin cancer, colon cancer, etc.) and the genetic subtype of the cancer (e.g., HER2+, HER triple negative, etc.). Before obtaining the sample, the cancer type and the genetic mutation that causes the cancer are known. The acquired breath sample and body fluid sample are associated with the cancer type. After procedure 450, the method proceeds to procedure 456.
[0156] In process 452, a sample of target cells exhibiting a selected gene mutation is obtained from a patient. Fig. 8A and Figure 8B In the example shown in , the target cells are cancer cells of the corresponding cancer type that exhibit the corresponding gene mutation. For example, these target cells are obtained by a biopsy procedure. After procedure 452, the method proceeds to procedure 458.
[0157] In process 454, a sample of healthy cells of the same type as the target cells is obtained from the patient. These healthy cells may also be obtained, for example, through a biopsy procedure. After process 454, the method proceeds to process 458.
[0158] At process 456, VOC emission data is obtained for at least one of the breath sample and the body fluid sample. Figure 1 , the analysis device 102 acquires the emission data of at least one of breath and body fluids. After procedure 456 , the method proceeds to procedure 468 .
[0159] In step 458, the target cells and healthy cells in the cell sample are cultured. After step 458, the method proceeds to step 460.
[0160] In procedure 460, the gene sequences of the cultured target cells and healthy cells are determined. Then, the molecular classification of the cell sample is verified based on known gene mutations. Since the classification of the gene mutations of the patient's target cells is usually known before sampling the target cells, only the classification needs to be verified. For example, there are currently more than 315 relevant mutations. This procedure is also called molecular classification. After procedure 460, the method proceeds to procedure 462.
[0161] In process 462, VOC emission data associated with both target cells and healthy cells are obtained. Figure 1 , the analysis device 102 acquires the emanation data related to both the target cells and the healthy cells. After the procedure 462 , the method proceeds to the procedure 464 .
[0162] In process 464, target cell VOC profiles for each of the selected genetic mutations (and thus corresponding cancer types) and healthy cell VOC profiles for each of the healthy cells are determined by comparing the target cell culture VOC emission data with the healthy cell culture VOC emission data. Figure 1 , the processor 106 generates a target cell VOC profile and a healthy cell VOC profile by comparing the target cell culture VOC emission data with the healthy cell culture VOC emission data. After procedure 464 , the method proceeds to procedure 466 .
[0163] In procedure 466, a predicted target cell VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the target cell VOC profile, and a predicted healthy cell VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the healthy cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Since the target cell VOC profile is associated with a selected gene mutation, the predicted target cell VOC profile is also associated with the same gene mutation. Reference Figure 1 , the processor 106 determines a predicted target cell VOC profile and a predicted healthy cell VOC profile from the target cell VOC profile and the healthy cell VOC profile. After procedure 466 , the method proceeds to procedure 468 .
[0164] In procedure 468, a dynamic differential VOC profile is generated from the predicted target cell VOC profile, the predicted healthy cell VOC profile, and the VOC emission data of the breath and body fluids. The dynamic differential VOC profile is generated by minimizing the error between the predicted target cell VOC profile and the VOC emission data of the breath sample and the body fluid sample. Since the predicted target cell VOC profile is associated with the corresponding gene mutation, the dynamic differential VOC profile is also associated with the gene mutation. Reference Figure 1 , the processor 106 determines a dynamic differential VOC profile. After procedure 468 , the method proceeds to procedure 470 .
[0165] In process 470, the dynamic differential VOC profile is stored in a database. Figure 1 , the processor 106 stores the VOC profile in the database 104 .
[0166] VOC profiles can be used to determine the efficacy of a treatment in an individual patient. However, to determine the efficacy of a treatment, it is necessary to determine the effect of a treatment that induces massive cell death (MCD) (e.g., chemotherapy, radiation therapy) on the VOCs emitted by the patient. This effect is determined by inducing MCD in cell culture in a manner that does not generate VOC artifacts (e.g., by using rapid freezing techniques or UV light techniques) and correlating the VOC emissions before and after MCD with corresponding target cells in the individual patient. Reference is now made to Fig. 9A and Fig. 9B , which are schematic diagrams of a method for correlating VOC emissions with corresponding target cells (eg, oncogenic cells) in an individual patient before and after MCD, operated in accordance with another embodiment of the disclosed technology.
[0167] In procedure 500, at least one of a breath sample and a body fluid (e.g., blood, urine, or sweat) sample is obtained from a patient for selected target cells and / or cell gene mutations. Similar to the above, the target cell type and gene mutation that causes the pathological condition are known before the sample is obtained. The obtained breath sample and body fluid sample are associated with the target cell type. After procedure 500, the method proceeds to procedure 506.
[0168] In process 502, for each selected target cell type, a target cell sample is obtained from a patient. The target cell type may be a target cell that exhibits a selected gene mutation or causes a pathological condition. Fig. 9A and Fig. 9B In the example shown in , the target cells are cancer cells of the corresponding cancer type that exhibit the corresponding gene mutation. Fig. 9A and Fig. 9B The method described in the invention is applied to any target cells. For example, these target cells are obtained by a biopsy procedure. After procedure 502, the method proceeds to procedure 508.
[0169] In process 504, a sample of healthy cells of the same type as the target cells is obtained from the patient. These healthy cells may also be obtained, for example, through a biopsy procedure. After process 504, the method proceeds to process 508.
[0170] At process 506, VOC emission data of at least one of a breath sample and a body fluid sample is obtained. Figure 1 , the analysis device 102 acquires the emission data of at least one of breath and body fluids. After procedure 506 , the method proceeds to procedure 528 .
[0171] In procedure 508, the gene sequences of target cells and healthy cells are determined. Then, the gene sequences are classified according to the known oncogene mutations of the selected cancer type. This procedure is also called molecular classification. After procedure 508, the method proceeds to procedure 510.
[0172] In step 510, target cells and healthy cells in a cell sample are cultured. After step 510, the method proceeds to steps 512 and 514.
[0173] In process 512, VOC emission data associated with both healthy cells and target cells is obtained. Figure 1 , the analysis device 102 acquires the emanation data related to both healthy cells and target cells. After procedure 512 , the method proceeds to procedure 518 .
[0174] At procedure 514, MCD is induced in the target cell culture and the healthy cell culture. Preferably, MCD is induced in a manner that does not generate VOC artifacts (e.g., by employing a flash freezing technique or a UV light technique). It should be noted that MCD is induced in the same target cell culture and the healthy cell culture used to acquire the VOC emission data before MCD. After procedure 514, the method proceeds to procedure 516.
[0175] At process 516, after inducing MCD in the target cell culture and the healthy cell culture, VOC emission data associated with the target cell culture and VOC emission data associated with the healthy cell culture are acquired. Figure 1 After MCD, the analysis device 102 acquires VOC emission data from both the target cell culture and the healthy cell culture. After procedure 516 , the method proceeds to procedure 520 .
[0176] At process 518, the VOC emission data of the target cell culture is compared with the VOC emission data of the healthy cell culture before MCD to differentiate between them. Figure 1 , the processor 106 compares the VOC emission data of the target cell culture with the VOC emission data of the healthy cell culture before MCD to distinguish therebetween. After procedure 518, the method proceeds to procedures 522 and 524.
[0177] In process 520, the VOC emission data of the target cell culture is compared with the VOC emission data of the healthy cell culture after MCD to distinguish between them. Figure 1 , the processor 106 compares the VOC emission data of the target cell culture with the VOC emission data of the healthy cell culture after MCD to distinguish therebetween. After procedure 520, the method proceeds to procedures 522 and 524.
[0178] In procedure 522, a pre-MCD target cell VOC profile and a post-MCD target cell VOC profile are generated by comparing the target cell culture VOC emission data before MCD with the target cell culture VOC emission data after MCD. Figure 1 The processor 106 generates a pre-MCD target cell VOC profile and a post-MCD target cell VOC profile by comparing the target cell culture VOC emission data before MCD with the target cell culture VOC emission data after MCD. After procedure 522 , the method proceeds to procedure 526 .
[0179] In procedure 524, a pre-MCD healthy cell VOC profile and a post-MCD healthy cell VOC profile are generated by comparing the healthy cell culture VOC emission data before MCD with the healthy cell culture VOC emission data after MCD. Figure 1 The processor 106 generates a pre-MCD healthy cell VOC profile and a post-MCD healthy cell VOC profile by comparing the healthy cell culture VOC emission data before MCD with the healthy cell culture VOC emission data after MCD. After procedure 524 , the method proceeds to procedure 526 .
[0180] In procedure 526, a predicted pre-MCD target cell VOC profile, a predicted post-MCD target cell VOC profile, a predicted pre-MCD healthy cell VOC profile, and a predicted post-MCD healthy cell VOC profile are determined. The predicted pre-MCD target cell VOC profile and the predicted post-MCD target cell VOC profile are determined by predicting VOC concentration levels in breath and body fluids from the pre-MCD target cell VOC profile and the post-MCD target cell VOC profile. The predicted pre-MCD healthy cell VOC profile and the predicted post-MCD healthy cell VOC profile are determined by predicting VOC concentration levels in breath and body fluids from the pre-MCD healthy cell VOC profile and the post-MCD healthy cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation f or the modified Farhi model, both of which are further described below). Since the pre-MCD target cell VOC profile and the post-MCD target cell VOC profile are associated with the selected gene mutation, the predicted pre-MCD target cell VOC profile and the predicted post-MCD target cell VOC profile are also associated with the same gene mutation. Figure 1 Processor 106 determines predicted VOC concentration levels in breath and body fluids from the pre-MCD target cell VOC profile, the post-MCD target cell VOC profile, the pre-MCD healthy cell VOC profile, and the post-MCD healthy cell VOC profile. From procedure 526 , the method proceeds to procedure 528 .
[0181] In procedure 528, a dynamic differential VOC profile is generated from the predicted pre-MCD target cell VOC profile, the predicted post-MCD target cell VOC profile, the predicted pre-MCD healthy cell VOC profile, the predicted post-MCD healthy cell VOC profile, and the VOC emission data of breath and body fluids. The dynamic differential VOC profile is generated by minimizing the error between the predicted pre-MCD target cell VOC profile, the post-MCD target cell VOC profile, and the VOC emission data of breath samples and body fluid samples. Since the predicted pre-MCD target cell VOC profile and the post-MCD target cell VOC profile are associated with corresponding gene mutations, the dynamic differential VOC profile is also associated with those gene mutations. Reference Figure 1 , the processor 106 determines a dynamic differential VOC profile. After procedure 528 , the method proceeds to procedure 530 .
[0182] In process 530, the dynamic differential VOC profile is stored in a database. Figure 1 , the processor 106 stores the dynamic differential VOC profile in the database 104 .
[0183] Reference now Fig. 10A , Fig. 10B and Fig. 10C , which are schematic diagrams of a method for identifying a personal treatment resistance VOC profile for an individual for a selected treatment, operating in accordance with another embodiment of the disclosed technology. In process 550, for example, according to the following in conjunction with the following Fig.13A , Fig. 13B , Fig. 13C , Fig.13D and Fig.13E The method as described, determines a personal treatment resistance VOC profile of an individual. After process 550, the method proceeds to process 552.
[0184] In step 552, target cells of the individual to be treated are cultured. After step 552, the method proceeds to step 554.
[0185] At process 554, prior to treatment, VOC emission data associated with the target cell culture is obtained. Figure 1 Prior to treatment, the analysis device 102 acquires VOC emission data associated with the target cell culture. After step 554, the method proceeds to step 556 and step 570.
[0186] At step 556, at least one selected treatment is administered to the target cell cultures. When the one or more selected treatments include more than one drug and / or therapy, the selected treatments are applied individually and in combination to different groups of corresponding target cell cultures. After step 556, the method proceeds to step 558 and step 562.
[0187] At process 558, VOC emission data for the target cell culture is acquired after at least one selected treatment has been applied to the target cell culture. Figure 1 After at least one selected treatment, the analysis device 102 acquires VOC emission data of the target cell culture. After step 558, the method proceeds to step 559 and step 568.
[0188] At process 559, a pre-treatment target cell VOC profile and a post-treatment target cell VOC profile are generated by individually comparing the pre-treatment target cell culture VOC emission data with the post-treatment target cell culture VOC emission data for each of the at least one treatment. Figure 1 The processor 106 generates a pre-treatment target cell VOC profile and a post-treatment target cell VOC profile by comparing the pre-treatment target cell culture VOC emission data with the post-treatment target cell culture VOC emission data. After procedure 559 , the method proceeds to procedure 560 .
[0189] In process 560, the target cell VOC profile before treatment and the target cell VOC profile after treatment are compared with the stored predicted complex treatment resistance VOC profile (e.g., such as the one described above in combination with Fig. 7A and Figure 7B The profiles are compared to those determined by the described methods to identify treatment resistance mutations. Figure 1 , the processor 106 compares the pre-treatment target cell VOC profile and the post-treatment target cell VOC profile with the stored predicted complex therapy resistance VOC profile to identify therapy resistance mutations. After procedure 560 , the method proceeds to procedure 562 .
[0190] At step 562 , target cells identified as developing therapy resistance mutations having corresponding post-treatment target cell VOC profiles and not present in the stored predicted complex therapy resistance VOC profiles are cultured separately to generate new target cell cultures. After step 562 , the method proceeds to step 566 .
[0191] At step 564, individually cultured target cells that exhibit treatment resistance mutations (i.e., identified in culture but not identified when the post-treatment target cell VOC profile is compared to the stored predicted complex treatment resistance VOC profile) are genetically sequenced and molecularly identified to identify and classify the treatment resistance mutations. After step 564, the method proceeds to step 566.
[0192] In process 566, VOC emission data for the new target cell culture is obtained. Figure 1, the analysis device 102 acquires VOC emission data of the new target cell culture. After procedure 566 , the method proceeds to procedure 568 .
[0193] At process 568, a new post-treatment target cell VOC profile is determined by comparing the pre-treatment target cell culture VOC emission data with the new post-treatment target cell culture VOC emission data. Figure 1 , the processor 106 determines a new post-treatment target cell VOC profile by comparing the pre-treatment target cell culture VOC emission data with the new post-treatment target cell culture VOC emission data. After procedure 568 , the method proceeds to procedure 570 .
[0194] In process 570, a complex personal therapy resistance VOC profile is determined by comparing VOC emission data obtained from target cells prior to treatment with the pre-treatment target cell VOC profile, with the post-treatment target cell VOC profile (i.e., associated with therapy resistance mutations identified using the stored predicted complex therapy resistance VOC profile), with the new post-treatment target cell VOC profile (i.e., associated with mutations identified using genetic sequencing and molecular recognition), and with VOC emission data obtained from new target cell cultures (i.e., associated with target cells that have developed therapy resistance). Reference Figure 1 , the processor 106 determines a complex personal treatment resistance VOC profile by comparing the VOC emission data obtained from the target cell culture before treatment with the target cell VOC profile before treatment, with the target cell VOC profile after treatment, with the new target cell VOC profile after treatment, and with the VOC emission data obtained from the new target cell culture. After procedure 570, the method proceeds to procedure 572.
[0195] In process 572, a predicted complex personal therapeutic resistance VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the complex personal therapeutic resistance VOC profile. The VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1 , the processor 106 determines a predicted complex personal treatment resistance profile. After procedure 572 , the method proceeds to procedure 574 .
[0196] In procedure 574, a dynamic complex therapy resistance VOC profile is determined by using the individual therapy efficacy VOC profile as a filter on the predicted complex therapy resistance VOC profile to mitigate artifacts not related to therapy resistance mutations. Figure 1, the processor 106 employs the stored individual treatment efficacy to mitigate artifacts unrelated to treatment resistance mutations on the predicted complex treatment resistance VOC profile, and determines a dynamic complex treatment resistance VOC profile. After procedure 574 , the method proceeds to procedure 576 .
[0197] In process 576, the dynamic complex personal treatment resistance VOC profile is stored in a database. Figure 1 , the processor 106 stores the dynamic complex personal treatment resistance VOC profile in the database 104 .
[0198] Use of stored VOC profiles
[0199] One use of VOC profiles is to determine whether a person carries an oncogene mutation, and further to identify which oncogene mutation is active in the person. To this end, VOC emission data from the person's breath and / or body fluids is sampled. The VOC emission data is then compared to a stored dynamic differential VOC profile (e.g., based on a combination of Figure 3A , Figure 3B and Figure 3C The method of the present invention is used to compare the VOC emission data with the dynamic differential VOC profiles determined by the method described in the present invention. As mentioned above, each of these stored dynamic differential VOC profiles is associated with a corresponding gene mutation. When a match between the VOC emission data and at least one stored dynamic differential VOC profile is detected, the patient is identified as carrying an oncogene mutation. In addition, the gene mutation associated with the dynamic differential VOC profile that best matches the acquired VOC emission data is identified as an active gene mutation.
[0200] The VOC profile stored in the database can be used to determine the efficacy of the treatment administered to the patient. Therefore, even during an extended treatment that may include multiple stages (e.g., chemotherapy, radiotherapy, drug therapy), VOC emission data can be obtained from the patient's breath and / or body fluids before treatment and it is established which of the dynamically differential or predicted VOC profiles stored in the database corresponds to the acquired VOC emission data to determine the efficacy of the treatment. VOC emission data of the breath and / or body fluids is also obtained after at least one selected stage of the selected treatment (i.e., between at least one of the treatment stages or the end of the treatment or any combination thereof). The VOC emission data obtained after at least one selected stage of the selected treatment is also compared with both the stored dynamically differential or predicted VOC profile and the VOC emission data obtained before the treatment to determine the efficacy of the administered treatment. In the case where VOC emission data for more than one stage of the treatment is obtained, these VOC emission data are compared with each other, with the VOC emission data before the treatment, and with the stored dynamically differential or predicted VOC profile. Where treatment of a patient has been initiated, the efficacy of the treatment may be determined by acquiring VOC emission data from the patient's breath and / or bodily fluids before and after a selected phase of the treatment. The VOC emission data acquired before the selected phase of the treatment is compared with the VOC emission data acquired after the selected phase of the treatment and a stored dynamically differentiated or predicted VOC profile to determine the efficacy of the treatment.
[0201] In addition, as mentioned above, MCD is used when determining the VOC profile. As will be further explained below, MCD is also used to determine the efficacy of the treatment in a manner that does not generate VOC artifacts. In general, the VOCs emitted by the target cells before and after treatment or after a stage of treatment may vary from patient to patient, from condition to condition, and from time to time when the VOCs are obtained. For example, the VOCs obtained during a woman's menstrual period and their concentration levels should be different from the VOCs obtained when the woman is not menstruating and their concentration levels. As another example, a patient may suffer from another medical condition (i.e., a condition other than the medical condition being treated). For this reason, the VOCs emitted by the target cells of such a patient and the concentration levels of these VOCs may be different from those of a patient who does not suffer from another medical condition.
[0202] Since the VOCs emitted by target cells before and after treatment or after a phase of treatment may vary from patient to patient, from condition to condition, and from time to time when the VOCs are obtained, it is beneficial to obtain information about the expected VOC emission after a phase of treatment or administration (i.e., which VOCs are emitted and at what concentration). When cells die, their membranes rupture. When the membranes rupture, the VOCs "trapped" within the cells are released. Therefore, when target cells have been treated and die, the concentration level of VOCs "trapped" within the cells is expected to rise. Inducing MCD destroys these target cells in a manner that does not generate VOC artifacts on the target cells. Measuring the concentration level of VOCs emitted by these destroyed cells provides information about the expected treatment outcome for a specific patient, as well as the corresponding genomic and medical condition at the time of treatment. It is expected that optimal treatment will destroy all target cells in the patient's body. Therefore, when the treatment is effective, the concentration values of VOCs associated with MCD (i.e., VOCs "trapped" within the cells) increase. To this end, the VOC concentration values of VOCs obtained from target cells after treatment or after a phase of treatment are compared with the VOC concentration values of VOCs obtained after induction of MCD, providing an indication of whether the treatment has achieved the desired result. As an additional indication of the efficacy of the treatment, the concentration values of VOCs associated with target cells decrease when the treatment is effective. In addition, the concentration values of VOCs associated with healthy cells remain unchanged when the treatment is effective. When the possibility of treatment resistance or mutation is not determined, as further described below, the treatment is more effective.
[0203] Reference now Fig.11 , which is a schematic diagram of a graph (generally labeled 580) of exemplary three VOC emission data 582, 584, and 586 associated with breast cancer in a particular patient according to another embodiment of the disclosed technology. Fig.11 In the example shown, VOC emission data 582, 584, and 586 relate to a specific patient with breast cancer. VOC emission data 582 shows the VOC emission of selected VOCs of healthy cells after MCD (i.e., directly for administration to a patient or culture - as further explained below). VOC emission data 584 shows the VOC emission of selected VOCs of target cells before MCD, while VOC emission data 586 shows the VOC emission of selected VOCs of target cells after MCD. Fig.11 As shown, the VOC marked as 100 exhibits a greater concentration value in the VOC emission data 586 (ie, after the MCD) than in the VOC emission data 584 (ie, before the MCD). Fig.11In the exemplary case shown, the VOC labeled 100 is 3-methylhexane. Thus, the optimal treatment in the case of breast cancer for the particular patient to which graph 580 relates would show 3-methylhexane as well as Fig.11 The concentration values of other VOCs are shown as increasing. Fig.11 Other VOCs measured in the HPLC-MS / MS are, for example, 2-ethylhexanol, 5-ethyl-3-methyloctane, acetone, ethanol, ethyl acetate, ethylbenzene, isononane, isoprene, nonanal, styrene, toluene and undecane.
[0204] Reference now Fig.12 , which is a schematic diagram of a method for determining therapeutic efficacy operated in accordance with another embodiment of the disclosed technology.
[0205] In procedure 600, a breath sample and / or a bodily fluid sample is obtained from a patient prior to at least one phase of treatment. After procedure 600, the method proceeds to procedure 602.
[0206] In process 602, VOC emission data of VOCs emitted by a breath sample and / or a body fluid sample is obtained prior to at least one phase of treatment. Figure 1 , the analysis device 102 acquires VOC emission data of VOCs emitted by the breath sample and / or the body fluid sample. After procedure 602 , the method proceeds to procedures 604 and 610 .
[0207] At process 604, a stored dynamic differential VOC profile corresponding to the acquired VOC emission data is identified (e.g., as combined with 4A to 4D , FIG. 5A to FIG. 5C , FIG. 6A to FIG. 6D and FIG. 7A to FIG. 7B The VOC emission data is determined by the stored dynamic differential VOC profile, thereby associating the pathological condition with the VOC emission data. Since the identified stored dynamic differential VOC profile is associated with the corresponding pathological condition, the acquired VOC emission data is also associated with the pathological condition (e.g., the corresponding oncogene mutation or the pathological condition caused by the pathogen). Generally, according to the above description, the stored dynamic differential VOC profile consists of at least one target cell VOC profile, and may also consist of a plurality of additional VOC profiles. Reference Figure 1 , the processor 106 identifies a dynamic differential VOC profile corresponding to the acquired VOC emission data. After procedure 604 , the method proceeds to procedure 606 .
[0208] At procedure 606 , a breath sample and / or a body fluid sample is obtained during and / or after at least one selected phase of the selected treatment. After procedure 606 , the method proceeds to procedure 608 .
[0209] At process 608, VOC emission data of VOCs emitted in a breath sample and / or a body fluid sample is obtained during and / or after at least one selected phase of a selected treatment. Figure 1 After the treatment, the analysis device 102 acquires VOC emission data of VOCs emitted in the breath sample and / or the body fluid sample. After procedure 608 , the method proceeds to procedure 610 .
[0210] In procedure 610, the efficacy of the treatment is classified at least by determining the concentration values of VOCs in the identified dynamic differential VOC profile acquired before the at least one stage of the treatment and the concentration values of VOCs in the identified dynamic differential VOC profile acquired during and / or after the at least one stage of the treatment. For example, when the concentration values of VOCs in the identified dynamic differential VOC profile during and after the treatment decrease relative to the concentration values of VOCs in the dynamic differential VOC profile identified before the treatment, the treatment can be classified as successful. Otherwise, the treatment can be classified as unsuccessful. To detect whether new mutations have occurred, the VOC emission data acquired before the treatment and during and / or after the treatment are compared with other dynamic differential VOC profiles stored in the database. If no new mutations have occurred (i.e., no other dynamic differential VOC profiles are identified in the database), the treatment can be considered successful. Reference Figure 1 , processor 106 determines the efficacy of the treatment.
[0211] As mentioned above, VOC profiles can be used to determine the efficacy of a treatment at a selected stage of a selected treatment, as well as to detect mutations that may render the treatment ineffective. For example, these VOC profiles can be used to determine the efficacy of chemotherapy. Furthermore, in the case of cancer treatment, VOC profiles can be used to determine whether cells have mutated into another cancer subtype during treatment, rendering the treatment ineffective.
[0212] Reference now FIG. 13A to FIG. 13E , which are schematic diagrams of a method for determining efficacy of a treatment in an individual, operated in accordance with another embodiment of the disclosed technology.
[0213] At procedure 650, at least one of a breath sample and a bodily fluid sample is obtained from the patient prior to applying the selected therapy. After procedure 650, the method proceeds to procedure 652.
[0214] At process 652, VOC emission data for at least one of a breath sample and a body fluid sample is obtained prior to at least one selected phase of a selected treatment. The VOC emission data for the breath sample and / or the body fluid sample obtained prior to at least one selected phase of a selected treatment is referred to as pre-treatment patient VOC emission data. Figure 1, the analysis device 102 acquires the emission data of at least one of the breath sample and / or the body fluid sample. From procedure 652 , the method proceeds to procedure 702 .
[0215] At step 654 , a target cell sample is obtained from a patient. From step 654 , the method proceeds to step 658 .
[0216] At step 656 , a sample of healthy cells of the same type as the target cells is obtained from the patient. From step 656 , the method proceeds to step 658 .
[0217] In procedure 658, two groups of target cell cultures (i.e., target cell culture 'A' and target cell culture 'B') and two groups of healthy cell cultures (i.e., healthy cell culture 'A' and healthy cell culture 'B') are generated from the target cell sample and from the healthy cell sample, respectively. Each group includes at least one culture. From procedure 658, the method proceeds to procedure 660.
[0218] In procedure 660, pre-treatment target cell culture VOC emission data associated with two target cell culture groups (i.e., target cell culture group 'A' and target cell culture group 'B') and pre-treatment healthy cell culture VOC emission data associated with two healthy cell cultures (i.e., healthy cell culture group 'A' and healthy cell culture group 'B') are obtained. Figure 1 , the analysis device 102 acquires VOC emission data associated with the two target cell cultures and the two healthy cell cultures. From procedure 660 , the method proceeds to procedures 662 , 680 , 682 , 684 , 686 , and 698 .
[0219] In procedure 662, a pre-treatment target cell VOC profile and a pre-treatment healthy cell VOC profile are determined by comparing the pre-treatment target cell culture VOC emission data of two groups of target cell cultures (i.e., target cell culture group 'A' and target cell culture group 'B') with the pre-treatment healthy cell culture VOC emission data of two groups of healthy cell cultures (i.e., healthy cell culture group 'A' and healthy cell culture group 'B'). Figure 1 , processor 106 determines a pre-treatment target VOC profile and a pre-treatment healthy cell VOC profile. From procedure 662 , the method proceeds to procedures 680 and 698 .
[0220] At process 664 , the selected treatment is applied to target cells in the first group of target cell cultures (ie, target cell culture group 'A'). From process 664 , the method proceeds to process 672 .
[0221] At step 666 , a large amount of cell death is induced on the target cells in the second group of target cell cultures (ie, target cell culture group 'B') in a manner that does not generate residual VOC artifacts (eg, by applying a flash freezing technique or ultraviolet-UV light technique to the target cell cultures). From step 666 , the method proceeds to step 674 .
[0222] At process 668 , the selected treatment is applied to healthy cells in the first group of healthy cell cultures (ie, healthy cell culture group 'A'). From process 668 , the method proceeds to process 676 .
[0223] At step 670 , a large amount of cell death is induced on healthy cells in a second group of healthy cell cultures (ie, healthy cell culture group 'B') in a manner that does not generate residual VOC artifacts (eg, by using a flash freezing technique or ultraviolet-UV light technique on the healthy cell cultures). From step 670 , the method proceeds to step 678 .
[0224] At process 672, after applying the treatment, post-treatment target cell culture VOC emission data associated with target cells in a first group of target cell cultures (ie, target cell culture group 'A') is obtained. Figure 1 After applying the treatment, the analysis device 102 acquires post-treatment target cell culture VOC emission data associated with the target cells in the first group of target cell cultures. After process 672, the method proceeds to processes 680 and 698.
[0225] At procedure 674, after inducing MCD, post-MCD target cell culture VOC emission data is acquired associated with target cells in a second target cell culture (ie, target cell culture group 'B'). Figure 1 After inducing MCD, the analysis device 102 acquires post-MCD target cell culture VOC emission data associated with the target cells in the second target cell culture. After procedure 674 , the method proceeds to procedure 682 .
[0226] At process 676, after applying the treatment, post-treatment healthy cell culture VOC emission data is obtained associated with cells in a first group of healthy cell cultures (ie, healthy cell culture group 'A'). Figure 1 After applying the treatment, the analysis device 102 acquires post-treatment healthy cell culture VOC emission data associated with healthy cells in the first group of healthy cell cultures. After procedure 676 , the method proceeds to procedure 684 .
[0227] At procedure 678, after inducing MCD, post-MCD healthy cell culture VOC emission data is acquired for cells in a second group of healthy cell cultures (ie, healthy cell culture group 'B'). Figure 1 After inducing the MCD, the analysis device 102 acquires post-MCD healthy cell culture VOC emission data associated with healthy cells in the second group of healthy cell cultures. After procedure 678 , the method proceeds to procedure 686 .
[0228] In procedure 680, a treatment-induced MCD target cell VOC profile is generated by comparing pre-treatment target cell culture VOC emission data of target cells in a first set of target cell cultures (i.e., target cell culture set 'A') with post-treatment target cell culture VOC emission data of target cells in a first set of target cell cultures (i.e., target cell culture set 'A'). The treatment-induced MCD target cell VOC profile relates to VOCs emitted by target cell culture set 'A' when MCD is induced by a selected treatment. Figure 1 The processor 106 generates a treatment-induced MCD target cell VOC profile by comparing the pre-treatment target cell culture VOC emission data of the target cells in the first set of target cell cultures with the post-treatment target cell culture VOC emission data of the target cells in the first set of target cell cultures. After procedure 680, the method proceeds to procedures 688 and 698.
[0229] In procedure 682, an MCD target cell VOC profile is generated by comparing pre-treatment target cell culture VOC emission data of target cells in a second group of target cell cultures (i.e., target cell culture group 'B') with post-MCD target cell culture VOC emission data of target cells in a second group of target cell cultures (i.e., target cell culture group 'B'). The MCD target cell VOC profile relates to VOCs emitted by target cell culture 'B' when MCD is induced in a manner that does not generate residual VOC artifacts (e.g., by employing a rapid freezing technique or an ultraviolet-UV light technique). Reference Figure 1 The processor 106 generates an MCD target cell VOC profile by comparing the pre-treatment target cell culture VOC emission data of the target cells in the second group of target cell cultures with the post-MCD target cell culture VOC emission data of the target cells in the second group of target cell cultures. After procedure 682, the method proceeds to procedures 690 and 698.
[0230] In procedure 684, a treatment-induced MCD healthy cell VOC profile is generated by comparing pre-treatment healthy cell culture VOC emission data of healthy cells in a first group of healthy cell cultures (i.e., healthy cell culture group 'A') with post-treatment healthy cell culture VOC emission data of healthy cells in a first group of healthy cell cultures (i.e., healthy cell culture group 'A'). The treatment-induced MCD healthy cell VOC profile relates to VOCs emitted by healthy cell culture 'A' when MCD is induced by a selected treatment. Reference Figure 1 The processor 106 generates a treatment-induced MCD healthy cell VOC profile by comparing pre-treatment healthy cell culture VOC emission data of healthy cells in the first group of healthy cell cultures with post-treatment healthy cell culture VOC emission data of healthy cells in the first group of healthy cell cultures.
[0231] In procedure 686, an MCD healthy cell VOC profile is generated by comparing pre-treatment healthy cell culture VOC emission data of healthy cells in a second group of healthy cell cultures (i.e., healthy cell culture group 'B') with post-MCD healthy cell culture VOC emission data of healthy cells in a second group of healthy cell cultures (i.e., healthy cell culture group 'B'). The MCD healthy cell VOC profile relates to VOCs emitted by healthy cell culture 'B' when MCD is induced in a manner that does not generate residual VOC artifacts (e.g., by employing a rapid freezing technique or an ultraviolet-UV light technique). Reference Figure 1 The processor 106 generates an MCD healthy cell VOC profile by comparing the pre-treatment healthy cell culture VOC emission data of the healthy cells in the second group of healthy cell cultures with the post-MCD healthy cell culture VOC emission data of the healthy cells in the second group of healthy cell cultures. After procedure 686 , the method proceeds to procedure 694 .
[0232] In procedure 688, a predicted treatment-induced MCD target cell VOC profile is determined by predicting VOC concentration levels in breath and / or body fluids from the treatment-induced MCD target cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1 , the processor 106 determines a predicted treatment-induced MCD target cell VOC profile. After procedure 688 , the method proceeds to procedure 696 .
[0233] In process 690, a predicted MCD target cell VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the MCD target cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1 , the processor 106 determines a predicted MCD target cell VOC profile. After procedure 690 , the method proceeds to procedure 696 .
[0234] In procedure 692, a predicted treatment-induced MCD healthy cell VOC profile is determined by predicting VOC concentration levels in breath and / or body fluids from the treatment-induced MCD healthy cell VOC profile. The VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1 , the processor 106 determines a predicted treatment-induced MCD healthy cell VOC profile. After procedure 692 , the method proceeds to procedure 696 .
[0235] In procedure 694, a predicted healthy MCD VOC profile is determined by predicting VOC concentration levels in breath and body fluids from the MCD healthy cell VOC profile. VOC concentration levels are predicted by using a diffusion model (such as the Farhi equation or the modified Farhi model, both of which are further described below). Figure 1 , the processor 106 determines a predicted MCD healthy cell VOC profile. After procedure 694 , the method proceeds to procedure 696 .
[0236] In procedure 696, a predicted treatment effect differential VOC profile is determined from the pre-treatment target cell VOC profile, the pre-treatment healthy cell VOC profile, the predicted treatment-induced MCD healthy cell VOC profile, the predicted treatment-induced MCD target cell VOC profile, the predicted MCD healthy cell VOC profile, and the predicted MCD target cell VOC profile. Figure 1 , the processor 106 determines a predicted treatment effect differential VOC profile. From procedure 696 the method proceeds to procedure 702.
[0237] In procedure 698, a dynamic treatment resistance likelihood differential VOC profile and at least one mutation rate differential VOC profile for at least one mutation and / or pathogen are determined. Initially, post-treatment target cell culture VOC emission data of target cells in target cell culture group 'A' are filtered with the MCD target cell VOC profile and the treatment-induced MCD target cell VOC profile to mitigate cell death-related VOCs. The filtered post-treatment target cell culture VOC emission data are compared with the pre-treatment target cell VOC profile to determine a dynamic treatment resistance likelihood profile. The concentration levels of the VOCs in the treatment resistance likelihood profile indicate the fraction of cells that survived the treatment without mutation.
[0238] The filtered post-treatment target cell culture VOC emission data is further filtered using the pre-treatment target cell VOC profile. The twice filtered post-treatment target cell culture VOC emission data is compared to a stored dynamic differential VOC profile (e.g., such as described above in conjunction with FIG. 3A to FIG. 3C , FIG. 5A to FIG. 5C and FIG. 6A to FIG. 6DThe concentration levels of the VOCs in these mutation rate differential VOC profiles are indicative of the mutation rates of the various mutations and pathogens (i.e., the fraction of cells that mutated during treatment and the number of new mutations that emerged after treatment). Figure 1 , the processor 106 determines a dynamic therapeutic resistance likelihood profile for each mutation and / or pathogen and one or more mutation rate differential VOC profiles. After procedure 698 , the method proceeds to procedure 710 .
[0239] At process 702, a dynamic therapeutic effect VOC profile is determined from the predicted therapeutic effect differential VOC profile and VOC emission data of VOCs emitted from a breath sample and / or a body fluid sample. Figure 1 , the processor 106 determines a dynamic treatment effect VOC profile. After procedure 702 , the method proceeds to procedure 704 .
[0240] In procedure 704, the selected treatment for the patient is started. After procedure 704, the method proceeds to procedure 706.
[0241] At procedure 706, at least one of a breath sample and / or a body fluid sample is obtained from the patient during and / or after at least one selected phase of the selected treatment. The breath sample and / or body fluid sample obtained from the patient during and / or after at least one selected phase of the selected treatment is referred to herein as post-treatment patient VOC emission data. After procedure 706, the method proceeds to procedure 708.
[0242] At process 708, post-treatment patient VOC emission data is obtained for VOCs emitted in breath samples and / or bodily fluid samples during and / or after at least one selected phase of a selected treatment. Figure 1 The analysis device 102 acquires VOC emission data of VOCs emitted in the breath sample and / or the body fluid sample during and / or after at least one selected phase of the selected treatment. After procedure 708 , the method proceeds to procedure 710 .
[0243] In process 710, the efficacy of at least one selected phase of a selected treatment administered to an individual patient (i.e., individual personal treatment efficacy) is determined from at least VOC emission data of breath samples and / or body fluid samples acquired before at least one selected phase of the selected treatment and VOC emission data of breath samples and / or body fluid samples acquired during and / or after at least one selected phase of the selected treatment (i.e., pre-treatment patient VOC emission data and post-treatment patient VOC emission data). To determine the efficacy of the selected phase of the selected treatment, the following are determined:
[0244] - Concentration values of VOCs in the pre-treatment target cell VOC profile prior to the selected phase of the selected treatment from the pre-treatment patient VOC emission data.
[0245] • Concentration values of VOCs in the pre-treatment target cell VOC profile during and / or after a selected phase of a selected treatment from post-treatment patient VOC emission data.
[0246] • Concentration values of VOCs in the predicted treatment-induced MCD target cell VOC profile prior to a selected phase of a selected treatment from pre-treatment patient VOC emission data.
[0247] • Concentration values of VOCs in a predicted treatment-induced MCD target cell VOC profile during and / or after a selected phase of a selected treatment from post-treatment patient VOC emission data.
[0248] • Concentration values of VOCs in the predicted MCD target cell VOC profile prior to a selected phase of a selected treatment from pre-treatment patient VOC emission data.
[0249] • Concentration values of VOCs in a predicted MCD target cell VOC profile during and / or after a selected phase of a selected treatment from post-treatment patient VOC emission data.
[0250] A selected phase of the selected treatment is determined to be effective when a concentration value of VOCs in an MCD target cell VOC profile predicted during and / or after a selected phase of treatment from post-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample is greater than a concentration value of VOCs in an MCD target cell VOC profile predicted prior to the selected phase of treatment from pre-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample.
[0251] Treatment is also determined to be effective when the concentration value of the VOC emission data from the pre-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile is greater than the concentration value of the VOC emission data from the post-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile.
[0252] The treatment is also determined to be effective when the concentration value of VOCs associated with the predicted treatment-induced MCD target cell VOC profile from the post-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample is greater than the concentration value of VOCs associated with the predicted treatment-induced MCD target cell VOC profile from the pre-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample.
[0253] In addition, to determine the efficacy of the selected phase of the selected treatment, the following are also determined:
[0254] - Concentration values of VOCs in a pre-treatment healthy cell VOC profile associated with healthy cells prior to a selected phase of a selected treatment from pre-treatment patient VOC emission data.
[0255] - Determining concentration values of VOCs in the pre-treatment healthy cell VOC profile during and / or after a selected phase of a selected treatment from the post-treatment patient VOC emission data.
[0256] • Concentration values of VOCs in the predicted treatment-induced MCD healthy cell VOC profile prior to a selected phase of a selected treatment from pre-treatment patient VOC emission data.
[0257] • Concentration values of VOCs in a predicted treatment-induced MCD healthy cell VOC profile during and / or after a selected phase of a selected treatment from post-treatment patient VOC emission data.
[0258] • Concentration values of VOCs in the predicted MCD healthy cell VOC profile prior to a selected phase of a selected treatment from pre-treatment patient VOC emission data.
[0259] • Concentration values of VOCs in the predicted MCD healthy cell VOC profile during and / or after a selected phase of a selected treatment from post-treatment patient VOC emission data.
[0260] The treatment is determined to be effective when the concentration value of the VOCs in the predicted treatment-induced MCD healthy VOCs from the post-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample remains unchanged relative to the concentration value of the VOCs in the predicted treatment-induced MCD healthy VOCs from the pre-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample (e.g., the difference between the values is within a predetermined threshold).
[0261] The efficacy of a selected phase of a selected treatment can also be determined from the concentration values of VOCs in the dynamic patient treatment resistance likelihood differential VOC profile and the concentration values of VOCs in the mutation rate differential VOC profile before the selected phase of the selected treatment and during and / or after the selected phase of the selected treatment. The concentration values of VOCs in the dynamic patient treatment resistance likelihood differential VOC profile and the mutation rate differential VOC profile before treatment are determined from the pre-treatment patient VOC emission data.
[0262] Concentration values of VOCs in a dynamic patient therapy resistance likelihood differential VOC profile and a mutation rate differential VOC profile during and / or after a selected phase of a selected therapy are determined from the post-treatment patient's VOC emission data. A selected phase of a selected therapy is determined to be effective when concentration values of VOCs in a dynamic patient therapy resistance likelihood differential VOC profile remain unchanged before and during and / or after a selected phase of a selected therapy. Furthermore, a selected phase of a selected therapy is determined to be effective when concentration values of VOCs in a mutation rate differential VOC profile remain unchanged during and / or after at least one selected phase of a selected therapy relative to concentration values of these VOCs before the selected phase of a selected therapy.
[0263] In addition, when no new mutations are identified, the selected phase of the selected treatment is determined to be effective. One or more new mutations are identified by comparing the post-treatment patient VOC emission data with the stored dynamic differential VOC profile. Before attempting to identify one or more new mutations, the post-treatment patient VOC emission data is filtered with the pre-treatment target cell VOC profile, the treatment-induced MCD target cell VOC profile, and the MCD target cell VOC profile, thereby mitigating information related to VOCs associated with the pre-treatment target cell VOC profile, the treatment-induced MCD target cell VOC profile, and the MCD target cell VOC profile.
[0264] refer to Figure 1 , processor 106 determines the efficacy of at least one selected phase of a selected treatment administered to the individual patient.
[0265] Another use of stored VOC profiles is to distinguish active from inactive mutations in patients and / or cultures. Fig.14 , which is a schematic diagram of a method for distinguishing between active mutations and inactive mutations in a patient and / or in culture, operated according to another embodiment of the disclosed technology.
[0266] At procedure 750, at least one of a breath sample and / or a bodily fluid sample is obtained from the patient. After procedure 750, the method proceeds to procedure 752.
[0267] At process 752, VOC emission data of VOCs emitted in a breath sample and / or a body fluid sample is obtained. Figure 1 , the analysis device 102 obtains VOC emission data of VOCs emitted in the breath sample and / or the body fluid sample. After procedure 752 , the method proceeds to procedure 766 .
[0268] In process 754, a target cell sample and a healthy cell sample are obtained from a patient. After process 754, the method proceeds to process 756.
[0269] In step 756 , target cells and healthy cells are subjected to gene sequencing, and molecular identification is performed to identify gene mutations. After step 756 , the method proceeds to step 758 .
[0270] In process 758, the target cell sample and the healthy cell sample are cultured. After process 758, the method proceeds to process 760.
[0271] At process 760, VOC emission data is obtained regarding VOCs emitted by the target cell culture and the healthy cell culture. Figure 1 , the analysis device 102 acquires VOC emission data related to VOCs emitted by the target cell culture and the healthy cell culture. After procedure 760 , the method proceeds to procedure 762 .
[0272] In process 762, a VOC profile of the target cell is determined by comparing the VOC emission data from the target cell culture with the VOC emission data from the healthy cell culture. Figure 1 , the processor 106 determines the VOC profile of the target cell by comparing the VOC emission data from the target cell culture with the healthy cell culture. After procedure 762 , the method proceeds to procedure 764 .
[0273] At process 764, one or more active mutations in the target cell culture are determined by comparing the target cell VOC profile with the stored dynamic differential VOC profile, as described above in conjunction with FIG. 3A to FIG. 3C , FIG. 5A to FIG. 5C , FIG. 7A to FIG. 7B , FIG. 8A to FIG. 8B and FIG. 10A to FIG. 10C Determined. Reference Figure 1 , the processor 106 determines one or more active mutations in the target cell culture from the mutation list received by gene sequencing by comparing the target cell VOC profile with the VOC profiles in the database 104. After procedure 764, the method proceeds to procedure 766.
[0274] At procedure 766, one or more active mutations in the patient are determined by comparing the patient's breath and / or body fluid VOC emission data with one or more identified dynamic differential VOC profiles (i.e., the one or more identified dynamic differential VOC profiles relate to a dynamic differential VOC profile identified by comparing the target cell VOC profile with a stored dynamic differential VOC profile). In addition, the breath and / or body fluid VOC emission data is filtered using the target cell VOC profile. In addition, the filtered breath and / or body fluid VOC emission data is compared with the stored dynamic differential VOC profile, as described above in conjunction with FIG. 3A to FIG. 3C , FIG. 5A to FIG. 5C , FIG. 7A to FIG. 7B , FIG. 8A to FIG. 8B and FIG. 10A to FIG. 10C Determined. Reference Figure 1 , processor 106 determines one or more active mutations in the patient.
[0275] Another use of the stored VOC profiles is to determine the best treatment for the patient. Fig.15A and Fig. 15B , which are schematic diagrams of a method for determining optimal treatment for a patient, operating in accordance with another embodiment of the disclosed technology.
[0276] In process 800, a target cell sample and a healthy cell sample are obtained from a patient. After process 800, the method proceeds to process 802.
[0277] In procedure 802, two groups of target cell cultures (i.e., target cell culture group 'A' and target cell culture group 'B') and two groups of healthy cell cultures (i.e., healthy cell culture group 'A' and healthy cell culture group 'B') are generated from the target cell sample and the healthy cell sample, respectively. Each group includes at least one culture. After procedure 802, the method proceeds to procedure 804.
[0278] In procedure 804, pre-treatment target cell culture VOC emission data related to VOCs emitted by target cells in two target cell culture groups (i.e., target cell culture group 'A' and target cell culture group 'B'), and pre-treatment healthy cell culture VOC emission data related to VOCs emitted by healthy cells in two healthy cell culture groups (i.e., healthy cell culture group 'A' and healthy cell culture group 'B') are obtained. Figure 1 , the analysis device 102 acquires pre-treatment target cell culture VOC emission data related to VOCs emitted by target cells from target cells in the two target cell culture groups, and pre-treatment healthy cell culture VOC emission data related to VOCs emitted by healthy cells from healthy cells in the two healthy cell culture groups. After procedure 804, the method proceeds to procedures 806, 826, 828, and 830.
[0279] In procedure 806, a pre-treatment target cell VOC profile and a pre-treatment healthy cell VOC profile are generated by comparing the pre-treatment target cell culture VOC emission data from two target cell culture groups (i.e., target cell culture group 'A' and target cell culture group 'B') with the pre-treatment healthy cell culture VOC emission data from two healthy cell culture groups (i.e., healthy cell culture group 'A' and healthy cell culture group 'B'). Figure 1, the processor 106 determines the pre-treatment target cell VOC profile and the pre-treatment healthy cell VOC profile by comparing the target cell culture VOC emission data from the target cell cultures in the two target cell culture groups with the healthy cell culture VOC emission data from the healthy cell cultures in the two healthy cell culture groups. After procedure 806, the method proceeds to procedures 808, 810, 820, 826, 828, and 830.
[0280] At procedure 808 , extensive cell death is induced on target cells in a first group of target cell cultures (ie, target cell culture group 'A') in a manner that does not generate residual VOC artifacts (eg, by employing flash freezing techniques or UV light techniques). From procedure 808 , the method proceeds to procedure 812 .
[0281] At procedure 810 , a large amount of cell death is induced on healthy cells in a first group of healthy cell cultures (ie, healthy cell culture group 'A') in a manner that does not generate VOC artifacts and does not generate residual VOCs (eg, by employing flash freezing techniques or UV light techniques). From procedure 810 , the method proceeds to procedure 814 .
[0282] At process 812, post-MCD target cell culture VOC emission data associated with target cells in a first group of target cell cultures (ie, target cell culture group 'A') is acquired. Figure 1 After inducing MCD, the analysis device 102 acquires post-MCD target cell culture VOC emission data associated with the target cells in the target cell culture 'A'. After procedure 812 , the method proceeds to procedure 816 .
[0283] At process 814, post-MCD healthy cell culture VOC emission data associated with healthy cells in a first group of healthy cell cultures (ie, healthy cell culture group 'A') is obtained. Figure 1 After inducing MCD, the analysis device 102 acquires post-MCD healthy cell culture VOC emission data associated with healthy cells in the healthy cell culture 'A'. After procedure 814 , the method proceeds to procedure 818 .
[0284] In process 816, an MCD target cell VOC profile is generated by comparing the pre-treatment target cell culture VOC emission data with the post-MCD target cell culture VOC emission data. The MCD target cell VOC profile relates to VOCs emitted by target cells in a first group of target cell cultures (i.e., target cell culture group 'A') when MCD is induced in a manner that does not generate residual VOC artifacts (e.g., by employing a flash freezing technique or a UV light technique). Reference Figure 1The processor 106 generates an MCD target cell VOC profile by comparing the pre-treatment target cell culture VOC emission data of the target cells in the first group of target cell cultures with the post-MCD target cell culture VOC emission data of the target cells in the first group of target cell cultures. After procedure 816, the method proceeds to procedures 826 and 828.
[0285] In procedure 818, an MCD healthy cell VOC profile is generated by comparing pre-treatment healthy cell culture VOC emission data of healthy cells in a first group of healthy cell cultures (i.e., healthy cell culture group 'A') with post-MCD healthy cell culture VOC emission data of healthy cells in a first group of healthy cell cultures (i.e., healthy cell culture group 'A'). The MCD healthy cell VOC profile relates to VOCs emitted by healthy cell culture 'A' when MCD is induced in a manner that does not generate residual VOC artifacts (e.g., by employing a flash freezing technique or a UV light technique). Reference Figure 1 The processor 106 generates an MCD healthy cell VOC profile by comparing the pre-treatment healthy cell culture VOC emission data of the healthy cells in the first group of healthy cell cultures with the post-MCD healthy cell culture VOC emission data of the healthy cells in the first group of healthy cell cultures. After procedure 818 , the method proceeds to procedure 830 .
[0286] In procedure 820, at least one selected treatment is applied to healthy cells in a second group of target cell cultures (i.e., target cell culture group 'B') and healthy cells in a second group of healthy cells (i.e., target cell culture group 'B'). In the event that more than one treatment is applied, the treatments are used as a reference for comparison to each other. From procedure 820, the method proceeds to procedure 824.
[0287] At process 822, for each selected treatment, post-treatment target cell culture VOC emission data associated with target cells in a second group of target cell cultures (ie, target cell culture group 'B') is obtained. Figure 1 For each selected treatment, the analysis device 102 obtains post-treatment target cell culture VOC emission data associated with the target cells in the second set of target cell cultures. After procedure 822, the method proceeds to procedures 826 and 828.
[0288] At procedure 824, for each selected treatment, post-treatment healthy cell culture VOC emission data is obtained associated with healthy cells in a second group of healthy cell cultures (ie, healthy cell culture group 'B') after application of the selected treatment. Figure 1For each selected treatment, after applying the selected treatment, the analysis device 102 obtains post-treatment healthy cell culture VOC emission data associated with healthy cells in the second group of healthy cell cultures. After procedure 824 , the method proceeds to procedure 830 .
[0289] In procedure 826, for each of the selected treatments, the likelihood of treatment resistance and the target cell mutation rate are determined. Both the likelihood of treatment resistance and the target cell mutation rate are used to determine whether the selected treatment is effective (i.e., the effectiveness of the treatment). Initially, the concentration values of VOCs in the pre-treatment target cell VOC profile are determined from the pre-treatment target cell culture VOC emission data associated with the target cell culture 'B' (i.e., the concentration level of the relevant VOCs before the treatment is determined). The post-treatment target cell culture VOC emission data is then filtered with the MCD target cell VOC profile to reduce cell death-related VOCs. The concentration values of VOCs in the pre-treatment target cell VOC profile are determined from the filtered post-treatment target cell culture VOC emission data (i.e., the concentration level of the relevant VOCs during and / or after the treatment is determined). The likelihood of treatment resistance for the selected treatment is determined by comparing the concentration values of VOCs in the pre-treatment target cell VOC profile before the selected treatment with the concentrations of VOCs in the pre-treatment target cell VOC profile during and / or after the selected treatment. Changes in the concentration levels of the relevant VOCs indicate the fraction of cells that survived the selected treatment without mutation. When the concentration value of the VOC in the pre-treatment target cell VOC profile decreases, the selected treatment is determined to be effective. When the concentration value of the VOC in the pre-treatment target cell VOC profile is zero, the selected treatment may be made most effective.
[0290] The filtered post-treatment target cell culture VOC emission data is further filtered using the pre-treatment target cell VOC profile. The mutation rate probability is determined by comparing the twice filtered post-treatment target cell culture VOC emission data with a stored dynamic differential VOC profile (e.g., such as described above in conjunction with FIG. 3A to FIG. 3C , FIG. 5A to FIG. 5C and FIG. 6A to FIG. 6DThe method comprises comparing the stored dynamic differential VOC profiles with the target cell culture VOC emission data after the twice-filtered treatment to identify one or more stored dynamic differential VOC profiles corresponding to the target cell culture VOC emission data after the twice-filtered treatment. Then, the concentration values of the VOCs in the one or more identified stored dynamic differential VOC profiles are determined from the target cell culture VOC emission data after the twice-filtered treatment. The concentration levels of the identified stored dynamic differential VOC profiles are indicative of various mutations and the mutation rate of the pathogen (i.e., the sites of the cell that mutated during the selected treatment and the number of new mutations that appeared after the selected treatment). When no newly stored dynamic differential VOC profiles are identified from the target cell culture VOC emission data after the twice-filtered treatment, the selected treatment is determined to be the most effective. When more than one selected treatment is employed, the optimal treatment may be determined by selecting the treatment that exhibits the greatest change in concentration levels of VOCs in the pre-treatment target cell VOC profile indicative of a reduction in the pre-treatment target cell VOC profile in the post-treatment target cell culture VOC emission data (i.e., most effective when the pre-treatment target cell VOC profile is no longer identified in the post-treatment target cell culture VOC emission data), and the treatment that exhibits the smallest change in concentration levels of VOCs in the identified stored dynamic differential VOC profiles within the post-treatment target cell culture VOC emission data when the stored dynamic differential VOC profiles are no longer identified in the post-treatment target cell culture VOC emission data, or when they are identified in all selected treatments. Reference Figure 1 , the processor 106 determines the likelihood of treatment resistance and the mutation rate. After procedure 826, the method proceeds to procedure 832.
[0291] In procedure 828, the effect of each selected treatment on the target cells is determined. To determine the effect of the selected treatment, the concentration values of the VOCs in the pre-treatment target cell VOC profile and the concentrations of the VOCs in the MCD target cell VOC profile before and after the treatment are determined. For this purpose, the concentration level of the VOCs in the pre-treatment target cell VOC profile is determined based on the pre-treatment target cell culture VOC emission data obtained from target cell culture 'B'. Moreover, the concentration level of the VOCs in the MCD target cell VOC profile is determined based on the pre-treatment target cell culture VOC emission data obtained from target cell culture 'A'. In addition, the concentration values of the VOCs in the pre-treatment target cell VOC profile are determined based on the post-treatment target cell culture VOC emission data obtained from target cell culture 'B', and the concentration values of the VOCs in the MCD target cell VOC profile are determined based on the post-treatment target cell culture VOC emission data obtained from target cell culture 'A'. The selected treatment is determined to be effective when the following occurs:
[0292] (a) the concentration value of the VOC emission data from the pre-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile is greater than the concentration value of the VOC emission data from the post-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile; and
[0293] (b) concentration values from the VOC emission data of the post-treatment target cell culture of VOCs associated with the MCD target cell VOC profile emitted by the post-treatment target cell culture are greater than concentration values from the VOC emission data of the pre-treatment target cell culture of VOCs associated with the MCD target cell VOC profile.
[0294] According to another example, a ratio between concentration values from VOC emission data of post-treatment target cell culture of VOCs associated with the MCD VOC profile emitted by the post-treatment target cell culture and concentration values from VOC emission data of post-treatment target cell culture of VOCs associated with the pre-treatment target cell VOC profile is greater than a ratio between concentration values from VOC emission data of pre-treatment target cell culture of VOCs associated with the MCD VOC profile and concentration values from VOC emission data of pre-treatment target cell culture of VOCs associated with the pre-treatment target cell VOC profile.
[0295] When more than one selected treatment is employed, the optimal treatment is determined from the selected treatments by determining the treatment in which the concentration level of the VOCs in the MCD target cell VOC profile exhibits the greatest increase and in which the concentration level of the VOCs in the pre-treatment target cell VOC profile exhibits the greatest decrease. Figure 1 , the processor 106 determines the effect of the selected treatment. After procedure 828, the method proceeds to procedure 832.
[0296] In procedure 830, the effect of each selected treatment on healthy cells is determined. To determine the effect of the selected treatment, the concentration values of the VOCs in the pre-treatment healthy cell VOC profile and the concentration values of the VOCs in the MCD healthy cell VOC profile before and after the selected treatment are determined. For this purpose, the concentration values of the VOCs in the pre-treatment healthy cell VOC profile are determined based on the pre-treatment healthy cell culture VOC emission data obtained from the target cell culture 'B'. Moreover, the concentration values of the VOCs in the MCD healthy cell VOC profile are determined based on the pre-treatment healthy cell culture VOC emission data obtained from the healthy cell culture 'A'. In addition, the concentration values of the VOCs in the pre-treatment healthy cell VOC profile are determined based on the post-treatment target cell culture VOC emission data obtained from the healthy cell culture 'B', and the concentration values of the VOCs in the MCD healthy cell VOC profile are determined based on the post-treatment healthy cell culture VOC emission data obtained from the healthy cell culture 'A'. The selected treatment is determined to be effective when the following occurs:
[0297] (a) concentration values from the post-treatment healthy cell culture VOC emission data for the VOCs in the pre-treatment healthy cell VOC profile remain unchanged relative to concentration values from the pre-treatment healthy cell culture VOC emission data for the VOCs associated with the pre-treatment healthy cell VOC profile; and
[0298] (b) Concentration values from post-treatment healthy cell culture VOC emission data for VOCs associated with the MCD healthy cell VOC profile remain unchanged relative to concentration values from pre-treatment healthy cell culture VOC emission data for VOCs in the MCD healthy cell VOC profile.
[0299] According to another example,
[0300] The concentration values from the post-treatment healthy cell culture VOC emission data of the VOCs associated with the MCD healthy cell VOC profile and the concentration values from the post-treatment healthy cell culture VOC emission data of the VOCs in the pre-treatment healthy cell VOC profile are equal to the concentration values from the pre-treatment healthy cell culture VOC emission data of the VOCs in the MCD healthy cell VOC profile and the concentration values from the pre-treatment healthy cell culture VOC emission data of the VOCs associated with the pre-treatment healthy cell VOC profile.
[0301] When more than one selected treatment is employed, the best treatment is determined from the selected treatments by determining the treatment that exhibits the smallest change in the concentration levels of VOCs in the MCD healthy cell VOC profile and the pre-treatment healthy cell VOC profile. Figure 1 , the processor 106 determines the effect of the selected treatment. After procedure 830, the method proceeds to procedure 832.
[0302] In procedure 832, a composite treatment response is determined for each selected treatment from four treatment effect parameters (i.e., effect of treatment on target cells, effect of treatment on healthy cells, likelihood of treatment resistance, and likelihood of mutation rate). When the selected treatment is determined to be effective in all four parameters, the composite treatment response is positive, and the treatment may be optimal. When more than one selected treatment is used, the treatment with the highest positive response in all four treatment effect parameters may be determined as the optimal treatment among the selected treatments. Reference Figure 1 , the processor 106 determines a composite treatment response from the four treatment effect parameters for each selected treatment.
[0303] Diffusion Model
[0304] As described above, the VOC concentration levels in breath and body fluids are predicted by using a diffusion model of VOCs from target cells and healthy cells to body fluids and breath. Specifically, a dynamic differential VOC profile is determined from a predicted target cell VOC profile, a predicted healthy cell VOC profile, and in some cases an additional predicted profile. Various predicted profiles are determined by predicting the VOC concentration levels of the relevant VOCs in the breath and body fluid VOC emission data based on target cell, healthy cell, and control cell metabolic rates and in vitro production rates. During the determination of the dynamic differential VOC profile, breath sample VOC emission data and body fluid sample VOC emission data are also used to minimize the possible error tolerance between the various predicted profiles and the actual results. One such model that relates alveolar VOC concentrations (i.e., in breath) to their potential blood concentrations is the Farhi equation, which takes the following form:
[0305]
[0306] C A (0) refers to the VOC concentration in alveoli (in parts per billion), relates to the mixed concentration in venous blood (in parts per billion), λ 血液:空气 Involving the blood-gas partition coefficient, involves air exchange (in litres per minute), and Relates to cardiac output in litres per minute.
[0307] The standard Farhi equation explained above refers only to possible VOC concentrations in the pulmonary (ie, lower part of the lung) compartment. This model may lead to erroneous results.
[0308] The model described below extends the standard Farhi equation (two-compartment model) to a three-compartment model (ie, the extended Farhi model). Fig.16, which is a schematic diagram of an extended Farhi model (generally designated 840) operating in accordance with another embodiment of the disclosed technology. Fig.16 As shown, the expanded Farhi model 840 includes three compartments, namely, the bronchial compartment 842, the alveolar compartment 844, and the body compartment 846. The bronchial compartment 842 and the alveolar compartment 844 are related to the lungs. The body compartment 844 (i.e., metabolism and production) combines the blood compartment and the tissue compartment of the body (i.e., any form of target cells, healthy cells or control cells from the body) into a volume with an effective volume. Since the blood and tissue compartments of the body are assumed to be in equilibrium and therefore can be combined into a single body compartment 844 (i.e., the body's blood and target, healthy, or control cell compartments) having an effective volume, the effective volume is given by:
[0309]
[0310] The use of a three-compartment model can be employed to produce a more accurate dynamic differential VOC profile. The three-compartment model incorporates the effects of upper respiratory tract (bronchial) and exhaled VOC concentrations in order to resolve known issues with the standard Farhi equation. The three-compartment model, described in detail below, also takes into account the effects of inhaled VOCs (ambient pollutants) on the exhaled breath concentrations of VOCs with higher Henry constants. The bronchial compartment 842 is considered to be a separate compartment divided into a gas phase and a mucus membrane, which is assumed to inherit the physical properties of water and act as a reservoir. The portion of the VOC dissolved in this layer is transferred to the bronchial circulation, whereby it is assumed that most of the associated venous drainage is connected to the pulmonary veins via post-capillary anastomosis. Therefore, at time 't', the amount of VOC delivered to the bronchial compartment 842 via exhalation and inhalation is equal to:
[0311]
[0312] in represents ventilation, C1 represents the concentration of the inhaled air (usually assumed to be zero), and C 支气管 represents the bronchial air concentration. The contribution of blood flow through primary veins via post-capillary osmosis is given by:
[0313]
[0314] in, represents the small portion of blood flow through the bronchioles, represents cardiac output, C a represents the arterial blood concentration, λ 粘液:血液 represents the mucus:blood partition coefficient, and λ 粘液:空气represents the temperature-dependent mucus:air partition coefficient. Then, the arterial blood concentration C a Given by:
[0315]
[0316] where λ 血液:空气 Represents the blood:air partition coefficient and C A Alveolar concentration.
[0317] The decrease in solubility in mucus with increasing temperature can be described by a Van't Hoff type equation within the ambient temperature range:
[0318]
[0319] where A and B (in Kelvin) are proportional to the entropy and enthalpy of volatilization, respectively. 血液:空气 37° C. is always referred to. Similarly, the partition coefficient λ between mucus and blood is 粘液:血液 is considered to be a constant defined by:
[0320] λ 粘液:血液 : =λ 粘液:空气 (37℃) / λ 血液:空气 (7)
[0321] The exchange between the bronchial compartment 842 and the alveolar compartment 844 is modeled as a diffusion process:
[0322] D(C A -C 支气管 ) (8)
[0323] The diffusion constant D takes values between zero and infinity.
[0324] The overall mass balance of the bronchial compartment 842 is given by:
[0325]
[0326] The mass balance of the alveolar compartment 844 is given by:
[0327]
[0328] And the mass balance of body compartment 846 is given by:
[0329]
[0330] where k 代谢 represents the total metabolic rate of the body, and k 产生 Indicates the generation rate. and represent the effective volumes of bronchioles, alveoli, and body, respectively. Moreover, C B is the concentration in the body, which is determined by Henry's law Correlation to mixed venous concentration where λ b:B Represents the blood:body tissue partition coefficient.
[0331] The total mass change of VOC (m 总 ):
[0332]
[0333] The total mass change of VOCs is given by the amount inhaled minus the amount exhaled plus the amount produced by the body minus the amount eliminated by metabolism (metabolism includes all losses, e.g., through liver, urine, skin, etc.) so that the total mass balance is satisfied.
[0334] VOC Filters
[0335] In the above description, all VOC emission data obtained from breath and / or body fluids and / or from cell cultures and comparisons therebetween can be used to detect common VOCs therein. These common VOCs can be used to define VOC filters. When new VOC emission data of breath and / or body fluids and / or cell cultures are obtained, this VOC filter can be used to filter common VOCs. This VOC filter can also be used to filter common VOCs in a VOC profile. The filter is constructed by comparing healthy VOC emission data of healthy cells of the same type from multiple patients and identifying VOCs associated with normal activities of these healthy cells. A diffusion equation (e.g., the Farhi equation discussed above) is used to generate a series of VOC concentration levels associated with normal activities. These VOC concentration levels associated with normal activities are used to filter these VOCs from the VOC emission data to identify abnormal concentrations.
[0336] VOC Profile Comparison
[0337] In the above embodiments, the VOC profiles are compared to each other. According to an alternative, the VOC profiles are compared by comparing polygons defined by the VOC profiles. The VOC profile can be considered as a two-dimensional Euclidean space, where the horizontal axis is defined by the VOC and the vertical axis is defined by the concentration level. In the VOC profile space, a polygon is defined by a reference point and a peak value of a selected VOC. The reference point can be the zero coordinate of the two-dimensional space. When comparing two VOC profiles, one or more identical polygons are defined in the two VOC profiles (i.e., using the same reference point and the same selected VOC). Then, for example, by using L between the turning functions of the two polygons p Distance, compares the two polygons to each other.
[0338] Increase VOC concentration
[0339] When determining VOC emission data in a breath sample, it may be desirable to increase the VOC in the lungs before sampling the breath. To this end, the patient is requested to exhale at their maximum capacity before sampling. Thereafter, the patient inhales and holds their breath for a predetermined duration (e.g., 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute) and exhales into a breath sample collector. The duration of each patient's breath holding is measured so that breath samples acquired can be correlated with different breath holding durations.
[0340] Furthermore, the methods detailed above for increasing the VOC concentration level in breath prior to sampling the breath can be combined with known methods in the art for sampling quantitative exhaled air from selected locations of the lungs (e.g., bronchi, alveoli, whole lung) to increase the VOC concentration levels of VOCs typically found in breath below the detection limit of the analytical device to levels where they can be detected, identified, and quantified. Fig.17A and Fig. 17B , which are schematic diagrams of a method for increasing VOC concentration prior to sampling and sampling a quantitative amount of air from a selected portion of the lungs, operated in accordance with another embodiment of the disclosed technology.
[0341] In procedure 850, the portion of the lung from which air is to be sampled and the volume of air to be sampled are selected. After procedure 850, the method proceeds to procedure 852.
[0342] In procedure 852, the inspiratory flow rate, expiratory flow rate, and carbon dioxide (CO2) concentration level are measured when the patient breathes normally for a certain duration (e.g., several breaths). The inspiratory flow rate and expiratory flow rate and CO2 concentration can be measured with a spirometer, which includes a flow meter and a CO2 sensor. After procedure 852, the method proceeds to procedure 854.
[0343] In procedure 854, the inspiratory flow rate, expiratory flow rate and CO2 concentration level are measured while the patient is exhaling and inhaling at his / her maximum capacity. After procedure 854, the method proceeds to procedure 856.
[0344] In procedure 856, a breathing pattern is determined that distinguishes between the bronchial portion of the exhaled air and the alveolar portion of the exhaled air. After procedure 856, the method proceeds to procedures 858 and 860.
[0345] At procedure 858, breath samples are acquired while the patient is exhaling at their maximum capacity, after the patient is exhaling at their maximum capacity, after the patient is inhaling at their maximum capacity, and after the patient holds their breath for at least a predetermined period of time. Each breath sample is associated with a corresponding moment in the determined breathing pattern. After procedure 858, the method proceeds to procedure 860.
[0346] In procedure 860 , a breath sample corresponding to the selected region of the lung is selected based on the breathing pattern and the associated time of the breath sample. After procedure 858 , the method proceeds to procedure 862 .
[0347] At process 862, VOC emission data is obtained from the obtained selected breath sample. Figure 1 , the analysis device 102 obtains VOC emission data from the selected breath sample. After procedure 862 , the method proceeds to procedure 864 .
[0348] In procedure 864, the duration of a patient's breath hold is measured to determine adjustments that may be necessary to correlate (ie, normalize) the different breath hold durations to the elevated concentration levels obtained within the acquired samples.
[0349] In some cases, the selected volume of air cannot be obtained in a single iteration. To this end, in each iteration, the procedure 858 can be repeated while the patient holds his breath for the same duration until the selected volume of air is obtained.
[0350] Those skilled in the art will appreciate that the disclosed technology is not limited to what has been particularly shown and described above. Rather, the scope of the disclosed technology is limited only by the following claims.
Claims
1. A method for determining the effect of at least one selected administered treatment on a metabolic, anabolism, catabolism, genetic and / or medical condition, the method comprising the following procedures: Obtain VOC emission data of target cell cultures before treatment; generating a pre-treatment target cell VOC profile from the VOC emission data of the pre-treatment target cell culture; The MCD target cell VOC profile was generated by: After inducing massive cell death (MCD) on an untreated target cell culture to generate a post-MCD target cell culture, obtaining post-MCD target cell culture VOC emission data associated with the target cells; After applying at least the at least one selected treatment to the target cell culture, for each selected treatment, obtaining VOC emission data for the target cell culture after treatment; and Determining the effectiveness of the selected treatment, wherein the treatment is determined to be effective when: (a) a concentration value of the VOC emission data from a pre-treatment target cell culture of a VOC associated with the pre-treatment target cell VOC profile is greater than a concentration value of the VOC emission data from a post-treatment target cell culture of a VOC associated with the pre-treatment target cell VOC profile; and (b) a concentration value from the VOC emission data of the post-treatment target cell culture of VOCs associated with the MCD target cell VOC profile emitted by the post-treatment target cell culture is greater than a concentration value from the VOC emission data of the pre-treatment target cell culture of VOCs associated with the MCD target cell VOC profile emitted by the pre-treatment target cell culture.
2. The method of claim 1, wherein the pre-treatment target VOC profile is generated by comparing the pre-treatment target cell culture VOC emission data from the target cells with pre-treatment healthy cell culture VOC emission data from healthy cells.
3. The method according to claim 1, wherein generating the MCD target cell VOC profile further comprises the following sub-procedures: The pre-treatment target cell culture VOC emission data associated with the target cells and the post-MCD target cell culture VOC emission data associated with the target cells are compared. The method of claim 3 , wherein the MCD is induced in a manner that does not generate residual VOC artifacts.
5. The method of claim 4, wherein the MCD is induced by applying one of flash freezing and ultraviolet light to the target cell culture.
6. The method of claim 1, wherein determining the effect of each of the at least one selected treatment on the target cells comprises the following sub-procedures: determining the concentration value of the VOC in the pre-treatment target cell VOC profile from the pre-treatment target cell culture VOC emission data; determining the concentration value of the VOC in the MCD target cell VOC profile from the pre-treatment target cell culture VOC emission data; determining the concentration value of the VOC in the pre-treatment target cell VOC profile from the post-treatment target cell culture VOC emission data; and The concentration values of the VOCs in the MCD target cell VOC profile are determined from the post-treatment target cell culture VOC emissions data.
7. The method of claim 6, wherein when the at least one selected treatment comprises at least two treatments, the treatment in which the concentration level of VOCs in the MCD target cell VOC profile exhibits the greatest increase and in which the concentration level of VOCs in the pre-treatment target cell VOC profile exhibits the greatest decrease is selected from the at least two treatments as the optimal treatment.
8. The method according to claim 1, further comprising the following procedure: Obtain VOC emission data of healthy cell cultures prior to treatment related to healthy cells; determining a pre-treatment healthy cell VOC profile by comparing the pre-treatment target cell culture VOC emission data from the target cell culture with the pre-treatment healthy cell culture VOC emission data from the healthy cell culture; and Generate MCD healthy cell VOC profile.
9. The method of claim 8, wherein generating the MCD healthy cell VOC profile comprises the following sub-routines: After inducing substantial cell death on the healthy cell culture, acquiring post-MCD healthy cell culture VOC emission data associated with the healthy cells; and The pre-treatment healthy cell culture VOC emission data associated with the healthy cells and the post-MCD healthy cell culture VOC emission data associated with the healthy cells are compared.
10. The method of claim 8, wherein the treatment is determined to be effective when: (a) the concentration value from the post-treatment healthy cell culture VOC emission data of the VOC in the pre-treatment healthy cell VOC profile remains unchanged relative to the concentration value from the pre-treatment healthy cell culture VOC emission data of the VOC associated with the pre-treatment healthy cell VOC profile; and (b) concentration values from the post-treatment healthy cell culture VOC emission data of VOCs associated with the MCD healthy cell VOC profile remain unchanged relative to concentration values from the pre-treatment healthy cell culture VOC emission data of VOCs in the MCD healthy cell VOC profile.
11. The method of claim 6, wherein when the at least one selected treatment comprises at least two treatments, and wherein the treatment in which the concentration levels of VOCs in the pre-treatment healthy cell VOC profile and the concentration levels of VOCs in the MCD healthy cell VOC profile show the smallest change is selected from the at least two selected treatments as the optimal treatment.
12. The method of claim 1, further comprising the step of determining the therapeutic resistance potential and the mutation rate of at least one mutation and / or pathogen.
13. The method of claim 12, wherein determining the likelihood of treatment resistance and at least one mutation rate comprises the following subroutines: determining the concentration value of the VOC in the pre-treatment target cell VOC profile from the pre-treatment target cell VOC emission data; filtering the post-treatment target VOC emission data using the MCD target cell VOC profile to mitigate cell death-related VOCs; determining the concentration value of the VOC in the pre-treatment target cell VOC profile from the filtered post-treatment target cell culture VOC emission data; comparing said concentration values of said VOCs in said pre-treatment target cell VOC profile before said at least one selected treatment and during and / or after said at least one selected treatment to determine said treatment resistance potential; as well as further filtering the filtered post-treatment target cell culture VOC emission data using the pre-treatment target cell VOC profile; comparing the twice filtered post-treatment target cell culture VOC emission data to a stored dynamic differential VOC profile to determine one or more at least one mutation rate differential VOC profile of at least one mutation or pathogen; as well as The concentration values of the VOCs in the one or more identified stored dynamic differential VOC profiles are determined from the twice filtered post-treatment target cell culture VOC emissions data.
14. The method of claim 13, wherein the at least one selected treatment is determined to be effective when the concentration value of the VOC in the pre-treatment target cell VOC profile decreases and when no stored dynamic differential VOC profile is identified from the twice-filtered post-treatment target cell culture VOC emission data.
15. The method of claim 13, wherein when the at least one selected treatment comprises at least two treatments, and wherein the treatment in which the concentration level of the VOC in the pre-treatment target cell VOC profile exhibits the greatest change and no stored dynamic differential VOC profile is identified or the treatment exhibiting the smallest change in the concentration level of the VOC in the identified stored dynamic differential VOC profile is selected from the selected treatments as the optimal treatment.
16. The method of claim 13, wherein the dynamic differential VOC profile relates to at least one of: The range of VOC emission data for each healthy cell VOC profile and target cell VOC profile; and Range between healthy cell VOC profile and target cell VOC profile.
17. A method for determining the efficacy of a treatment for a metabolic, anabolic, catabolic, genetic and / or medical condition administered to a patient, the method comprising the following procedures: obtaining pre-treatment patient VOC emission data of VOCs emitted from at least one of a breath sample and a bodily fluid sample prior to at least one selected phase of the treatment; Obtain VOC emission data of target cell cultures before treatment; The predicted MCD target cell VOC profile was generated by: (a) after inducing massive cell death (MCD) on an untreated target cell culture to generate a post-MCD target cell culture, obtaining VOC emission data of the post-MCD target cell culture; as well as (b) using a diffusion model to predict the concentration level of the VOC in the breath and / or the body fluids; after applying the selected treatment to the patient, obtaining post-treatment patient VOC emission data of the VOCs emitted from at least one of breath samples and bodily fluid samples obtained during and / or after at least one selected phase of the treatment; as well as The efficacy of the selected treatment is determined, and the treatment is determined to be effective when the concentration value of the VOC in the predicted MCD target cell VOC profile during and / or after the selected stage of the treatment from the post-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample is greater than the concentration value of the VOC in the predicted MCD target cell VOC profile before the selected stage of the treatment from the pre-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample.
18. The method according to claim 17, further comprising the following procedure: generating a pre-treatment target cell VOC profile from said VOC emissions of said pre-treatment target cell culture; After applying at least the at least one selected treatment to the target cell culture, generating a predicted treatment-induced MCD target cell VOC profile by: (a) acquiring VOC emission data of the VOC associated with the target cell culture after MCD; and (b) using a diffusion model to predict the concentration level of the VOC in the breath and / or the body fluids, The treatment is determined to be effective when the concentration value of the VOC associated with the predicted treatment-induced MCD target cell VOC profile from the post-treatment patient VOC emission data associated with at least one of the respiratory sample and the body fluid sample is greater than the concentration value of the VOC associated with the predicted treatment-induced MCD target cell VOC profile from the pre-treatment patient VOC emission data associated with at least one of the respiratory sample and the body fluid sample.
19. The method of claim 17, wherein the procedure for determining the efficacy of a personal treatment for an individual comprises the following procedure: generating a pre-treatment target cell VOC profile from said VOC emissions of said pre-treatment target cell culture; The MCD target cell VOC profile was generated by: After inducing extensive cell death on an untreated target cell culture to produce a post-MCD target cell culture, acquiring VOC emission data for the post-MCD target cell culture; After applying at least the at least one selected treatment to the target cell culture, for each selected treatment, obtaining VOC emission data for the target cell culture after treatment, in, The treatment is also determined to be effective when the concentration value of the VOC emission data from the pre-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile is greater than the concentration value of the VOC emission data from the post-treatment target cell culture of the VOC associated with the pre-treatment target cell VOC profile.
20. The method of claim 17, wherein the procedure for determining the efficacy of a personal treatment for an individual comprises the following sub-procedures: Determining at least one of at least one mutation and / or a pathogen's dynamic therapy resistance potential differential VOC profile and at least one mutation rate differential VOC profile from the stored dynamic differential VOC profiles and the post-treatment patient VOC emission data ; as well as determining concentration values of the VOCs in the dynamic patient treatment resistance potential differential VOC profile and in the mutation rate differential VOC profile from the pre-treatment target cell culture VOC emission data; as well as Concentration values of the VOCs in the dynamic patient treatment resistance potential differential VOC profile and in the mutation rate differential VOC profile are determined from the post-treatment patient VOC emission data.
21. The method of claim 20, wherein the treatment is determined to be effective when the concentration values of the VOCs in the dynamic patient treatment resistance likelihood differential VOC profile and in the mutation rate differential VOC profile remain unchanged during and / or after the at least one stage of the treatment relative to the concentration values of the VOCs before the at least one stage of the treatment.
22. The method according to claim 17, further comprising the following procedure: After applying at least the at least one selected treatment to the healthy cell culture, generating a predicted treatment-induced MCD healthy cell VOC profile by: (a) obtaining VOC emission data of the VOC associated with the treated healthy cell culture; and (b) using a diffusion model to predict the concentration level of the VOC in the breath and / or the body fluids, in, The treatment is determined to be effective when the concentration value of the VOCs in the predicted treatment-induced MCD healthy cell VOC profile from the post-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample remains unchanged relative to the concentration value of the VOCs in the predicted treatment-induced MCD healthy cell VOC profile from the pre-treatment patient VOC emission data associated with at least one of the breath sample and the body fluid sample.
23. The method of claim 22, wherein the procedure for determining the efficacy of a personal treatment for an individual comprises the following sub-procedures: determining, from the pre-treatment healthy cell culture VOC emission data, a concentration value of the VOC in the pre-treatment healthy cell VOC profile associated with the healthy cells prior to the at least one stage of the treatment; determining, from the post-treatment patient VOC emission data, concentration values of the VOCs in the pre-treatment healthy cell VOC profile associated with the healthy cells during and / or after the at least one phase of the treatment; determining, from the pre-treatment healthy cell culture VOC emission data, concentration values of the VOCs in the predicted treatment-induced MCD healthy cell VOC profile prior to the at least one phase of the treatment; determining, from the post-treatment patient VOC emission data, concentration values of the VOCs in the predicted treatment-induced MCD healthy cell VOC profile during and / or after the at least one phase of the treatment; determining, from the pre-treatment healthy cell culture VOC emission data, a concentration value for the VOC in the predicted MCD healthy cell VOC profile prior to the at least one phase of the treatment; as well as Concentration values of the VOCs in the predicted MCD healthy cell VOC profile during and / or after the at least one phase of the treatment are determined from the post-treatment patient VOC emission data.
24. The method of claim 17, wherein prior to the procedure of determining the pre-treatment target cell VOC profile and the pre-treatment healthy cell VOC profile, the method further comprises the following procedure: obtaining VOC emission data of the VOC emitted from the at least one of a breath sample and a body fluid sample obtained from the patient prior to administering the treatment; Prior to administering the treatment, obtaining pre-treatment target cell culture VOC emission data associated with two target cell culture groups and pre-treatment healthy cell culture VOC emission data associated with two healthy cell culture groups, wherein the two target cell culture groups are generated from target cell samples obtained from the patient prior to administering the treatment, and the two healthy cell culture groups are generated from the healthy cell samples of the same cell type as the target cells.
25. The method of claim 24, wherein after said procedure of determining a pre-treatment VOC profile and before said procedure of generating a predicted treatment-induced target MCD VOC profile, said method further comprises the procedure of: After applying the selected treatment to cells in a first one of the group of target cell cultures and in a first one of the group of healthy cell cultures, acquiring post-treatment VOC emission data associated with the target cell culture and with the healthy cell culture following the application of the treatment; and After inducing substantial cell death of the cells in a second one of the groups of target cell cultures and in a second one of the groups of healthy cell cultures, obtaining post-MCD VOC emission data associated with the second group of target cell cultures and with the second group of healthy cell cultures after the induction of MCD.
26. The method of claim 17, wherein said at least one stage of treatment is determined to be effective when no new mutations are identified, Therein novel mutations are identified by attempting to identify stored dynamic differential VOC profiles corresponding to said post-treatment patient VOC emission data.
27. The method of claim 26, wherein prior to said attempt to identify new mutations, said post-treatment patient VOC emission data is filtered with said pre-treatment target cell VOC profile, with said treatment-induced MCD target cell VOC profile, and with said MCD target cell VOC profile, thereby mitigating information related to said VOCs caused by said treatment.
28. A method for determining the efficacy of a treatment administered to a patient, the method comprising the following procedures: after obtaining at least one of a breath sample and a body fluid sample prior to at least one phase of the treatment, obtaining VOC emission data of VOCs emitted by the at least one of the breath sample and the body fluid sample obtained prior to the at least one phase of the treatment; identifying a stored dynamic differential VOC profile corresponding to the acquired VOC emissions data, thereby correlating a pathological condition with the VOC emissions data; after obtaining at least one of a breath sample and a body fluid sample during and / or after said at least one phase of said treatment, obtaining VOC emission data of said VOC emitted in said at least one of a breath sample and a body fluid sample obtained during and / or after said at least one phase of said treatment; as well as classifying the efficacy of the treatment by at least comparing concentration values of the VOCs in the identified dynamic differential VOC profile acquired before the at least one phase of the treatment with concentration values of the VOCs in the identified dynamic differential VOC profile acquired during and / or after the at least one phase of the treatment, Wherein said at least one stage of said treatment is classified as successful when the concentration level of said VOC associated with said target cell VOC profile in said dynamic differential VOC profile decreases during and / or after said selected stage of said treatment relative to said concentration value of said VOC in said identified dynamic differential VOC profile prior to said treatment.
29. The method of claim 28, wherein the treatment is classified as successful also when no new mutations are detected.
30. The method of claim 29, wherein new mutations are detected by comparing the VOC emission data acquired before the at least one phase of the treatment with the VOC emission data acquired during and / or after the at least one phase of the treatment, and with other stored dynamic differential VOC profiles.
31. A method for determining the effect of at least one selected treatment administered to a patient on a metabolic, anabolism, catabolism, genetic and / or medical condition, the method comprising the following procedures: Obtain VOC emission data of target cell cultures before treatment; generating a pre-treatment target cell VOC profile from said VOC emissions of said pre-treatment target cell culture; The MCD target cell VOC profile was generated by: After inducing massive cell death on an untreated target cell culture (MCD) to produce a post-MCD target cell culture, obtaining VOC emission data for the post-MCD target cell culture; After applying at least the at least one selected treatment to the target cell culture, for each selected treatment, acquiring VOC emission data for the target cell culture after treatment; The effect of the selected treatment is determined, and the treatment is determined to be effective when a ratio between concentration values from the VOC emission data of the target cell culture after treatment of VOCs associated with the MCD VOC profile and concentration values from the VOC emission data of the target cell culture after treatment of VOCs associated with the pre-treatment target cell VOC profile is greater than a ratio between concentration values from the VOC emission data of the target cell culture before treatment of VOCs associated with the MCD VOC profile and concentration values from the VOC emission data of the target cell culture before treatment of VOCs associated with the pre-treatment target cell VOC profile.
Citation Information
Patent Citations
VOC-based narcolepsy diagnostic method
WO2014180974A1
The use of bioinformatic data in autologous cell therapies
CN107787492A
Bioreactor for quantification of headspace VOC content from cultures
US20110059476A1
